

YOUR IMPACT BEGINS HERE, TODAY!

AASLD
The Liver
Meeting®



2025 PROGRAM GUIDE AS OF SEPT. 30TH

NOVEMBER 7-11

• Washington, D.C.

• aasld.org/the-liver-meeting

TABLE OF CONTENTS

PRESIDENT'S WELCOME	3
AASLD'S GLOBAL FOOTPRINT	4
MOBILE APP & TLMdX ACCESS	5
AASLD FOUNDATION	6
NAVIGATING #TLM25	8
CONNECT WITH IMPACT: #TLM25 NETWORKING EVENTS	12
ONE PROGRAM. COUNTLESS OPPORTUNITIES.	14
EXHIBIT HALL: INNOVATION IN ACTION	49
BIG IMPACT, SUPPORTED BY SPONSORS	56
YOUR GUIDE TO #TLM25	57

PRESIDENT'S WELCOME

As President of the American Association for the Study of Liver Diseases (AASLD), it is my great pleasure to welcome you to The Liver Meeting® 2025 (TLM) in Washington, D.C.!

Our annual gathering is where the world's leading minds in hepatology are united by one shared purpose: *Impact*. This year's theme, *Impact*, reflects the breakthroughs and discoveries we celebrate here and the collective power of our community to come together and change lives. Together, we represent the full continuum of liver health, as clinicians, researchers, educators, advocates, and patients working side by side to move the field forward. Every conversation, collaboration, and connection at TLM ripples beyond the borders of our field to advance research, improve care, and transform outcomes across the globe.

This year, I'm proud to welcome over 8,000 attendees and presenters from more than 80 countries, reflecting our shared commitment to advancing hepatology worldwide. I'm also proud to share that TLM25 is breaking records with the largest patient attendance in AASLD's history, underscoring our commitment to integrating patient perspectives into every aspect of hepatology.

This year's program showcases the depth and diversity of expertise that defines our field. Our scientific programming at TLM continues to set the standard for excellence and innovation in hepatology.

- TLM25 features 98 of 100 scientific sessions developed in partnership with AASLD's Special Interest Groups (SIGs) and Committees, representing programming designed *by members for members*. This member-driven content ensures that our programming is scientifically rigorous, relevant, and connected to the challenges and opportunities shaping liver health today.
- Nearly 3,000 abstracts represent the most current and compelling research from across the world.
- More than 265 hours of session programming, featuring today's leading experts alongside the next generation of hepatology innovators, translates science into impact by advancing discovery, improving care, and inspiring collaboration.
- And innovation comes to life in two TLM Theaters, where industry leaders and scientific experts will share cutting-edge research and solutions through dynamic presentations and interactive discussions.

At TLM, your education and learning happen both inside and outside the session rooms. We're also focused on bringing together the people, partners, and innovations that drive progress across the field.

- New this year, Science in the Park Meet-Ups provide space to share ideas, build relationships, and strengthen science.
- This year's exhibit floor is the largest to date—featuring nearly 150 exhibitors, including more than 30 new exhibitors—and will display the latest innovations, technologies, and solutions shaping the future of liver health and patient care.
- Special sessions and experiences include the State-of-the-Art Lecture, exploring the latest frontier in liver science, and the POCUS Hands-On Workshops offering practical skills.
- And you won't want to miss the Members' Reception, one of the most anticipated gatherings at TLM! Join more than 1,500 AASLD members on Sunday, Nov. 9 at 7:30 p.m. to celebrate our community.

TLM is where science and community intersect.

As we convene in Washington, D.C., our impact lies in our community. Whether you're sharing your research, mentoring, or discovering new tools and technologies, TLM is your space to engage, learn, and collaborate. Through our collective efforts, AASLD continues to realize our mission to advance and disseminate the science and practice of hepatology and to promote liver health and quality patient care.

Together, we'll foster innovation and deliver education that empowers every member of our field to make an impact: one patient, one discovery, one idea at a time.

On behalf of AASLD's leadership, thank you for your commitment, for being part of this community, and for the impact you make every day. I look forward to an inspiring and memorable meeting with all of you at TLM25.

Warm regards,

GRACE L. SU, MD, FAASLD
President, AASLD



AASLD'S GLOBAL FOOTPRINT

The Liver Meeting unites the world in hepatology with their global network of representing over **80 countries**.



AASLD and its global partners are united under one mission: to prevent and cure liver disease.



#TLM25 IN THE PALM OF YOUR HAND

Your meeting, your schedule, your app — designed to keep you connect every step of the way.



COMPLIMENTARY WI-FI

Available throughout the convention center

NETWORK/SSID: AASLD

PASSWORD: MASH2025

Sponsored by



RELIVE #TLM25 FROM ANYWHERE WITH **TLMdX®**

TLMdX® brings the science to you even after the meeting ends.
Access online sessions within 72 hours of the in-person presentation.



AASLD FOUNDATION

EMPOWERING THE NEXT GENERATION OF LEADERS IN HEPATOLOGY

AASLD Foundation is committed to fostering innovation and excellence in liver disease training and research to create a brighter and healthier tomorrow for patients and their families. **As a solely donor-funded organization, every dollar directly funds the future of hepatology** – supporting innovative research, career development, advanced training, and mentorship that equip the next generation of hepatologists to lead the field.

Together, we are accelerating discovery, strengthening the hepatology workforce, and advancing the understanding and treatment of liver disease.

View the 2025 grant recipients outside the General Session on level 1 (Exhibit Hall A).


AWARDS & HONORS GALA

The Awards & Honors Gala is an unforgettable evening of celebration, connection, and purpose as we honor the visionaries transforming the future of liver research, health, and care. As the first Awards & Honors Gala, the evening featured heartfelt tributes and recognition of leaders whose groundbreaking contributions are shaping hepatology today and inspiring the next generation.

Thank you to all those who attended and sponsored the event!

WALK OF HONOR

Debuting this year, the Walk of Honor recognizes a mentor, colleague, or leader in hepatology. Showcased at the General Session entrance and unveiled during the Honors & Awards Gala on Friday evening, each tribute celebrates past legacies while supporting the future of hepatology. All proceeds directly fund AASLD Foundation's mission to advance research, education, and innovation in liver health.




CLUB 1950: SHAPING THE FUTURE OF HEPATOLOGY

Honoring AASLD's founding year, Club 1950 represents the pinnacle of leadership – a distinguished society of visionaries, trailblazers, and innovators who contribute \$1,950 annually. Members enjoy premier benefits at The Liver Meeting, including a dedicated registration desk, access to **Clubhouse 1950** – a private lounge offering full breakfast, lunch, refreshments, and premium amenities – reserved **General Session Club Seats**, and exclusive donor gifts.

Club 1950 is where leadership, legacy, and impact meet.

VIEW THE 2025 CLUB 1950 LIST ONLINE.



VIP* DONOR ACCESS AT THE LIVER MEETING

We are proud to recognize our VIP Donors—supporters who have contributed \$500 or more to AASLD Foundation. As a special thank you, VIP Donors enjoy access to the VIP Donor Lounge – a welcoming space to relax, connect, and recharge during the meeting.

**JOIN THIS VALUED COMMUNITY BY DONATING
ONLINE TODAY OR VISITING THE FOUNDATION
BOOTH ON THE L-STREET BRIDGE.**




**Exclusive to donors who made a gift of \$500+ in 2025 or by special invitation.*


NAVIGATING #TLM25

Navigate TLM using these maps to find sessions and key locations. This is your guide to getting around efficiently and making the most of your experience. For the most up-to-date maps, download the TLM mobile app.

STREET LEVEL




LEVEL TWO




NAVIGATING #TLM25

Navigate TLM using these maps to find sessions and key locations. This is your guide to getting around efficiently and making the most of your experience. For the most up-to-date maps, download the TLM mobile app.

CONCOURSE LEVEL



LEVEL THREE



	RESTROOMS		ESCALATORS
	RESTROOMS		STAIRS
	RESTROOMS		COFFEE
	HANDICAP RESTROOMS		INFORMATION
	ALL INCLUSIVE RESTROOM		PHONES
	FIRST AID		FOOD & BEVERAGE
	DRINKING FOUNTAIN		NURSING MOTHER

CONNECT WITH IMPACT: #TLM25 NETWORK

Attend dedicated networking events designed to spark meaningful conversations and lasting connections. *Check the mobile app for locations!*

FRIDAY, NOV. 7

7:00-8:00 AM	 Patient Welcome Breakfast, Room 202
8:00 AM-NOON	 LLC Summit, Room 143
9:45-10:45 AM	Meet-Ups at The Park @ TLM • ELS Alumni, Space 3 • First First Timers & Social Media Ambassadors, Space 1-2
5:30-6:30 PM	SIG Meet-Ups at The Park @ TLM: • Liver Cell Biology, Space 1 • Liver Fibrosis, Space 2 • ALD, Space 3 • LT&S, Space 4 • Portal Hypertension, Space 5
7:30-9:00 PM	 Awards and Honors Gala

SATURDAY, NOV. 8

7:00-8:00 AM	 SIG Leadership Breakfast, Room 206
9:45-10:45 AM	Meet-Ups at The Park @ TLM • AASLD Foundation, Research & Career Development Awardees, Space 1 • Primary Biliary Cholangitis (PBC) Patient, Space 2 • Diversity, Space 3-4
12:30-1:00 PM	 Leadership Luncheon, Room 206
12:30-2:00 PM	Meet-Ups at The Park @ TLM  • Masterclass, Space 1
1:00-2:00 PM	 Annual Business Meeting Room 206
3:45-4:45 PM	Meet-Ups at The Park @ TLM • Clinician and Medical Educators, Space 1 • Patient Meet-Up - MASLD/MASH, Space 2 <i>Sponsored by: Madrigal Pharmaceuticals</i>
6:00-7:30 PM	Exhibit Hall Opening Reception <i>Sponsored by: Mirum Pharmaceuticals</i>
7:00-8:00 PM	 Global Reception
7:30-8:30 PM	PRIDE Reception, Marriott Marquis, Room: University of D.C. <i>Sponsored by: Gilead Sciences</i>

WORKING EVENTS

SUNDAY, NOV. 9

9:45-10:45 AM	Meet-Ups at The Park @ TLM - AASLD/ALEH, Space 1 - VA Premium, Space 3
12:30-2:00 PM	Past Presidents' Luncheon, Room 206
3:45-4:45 PM	Meet-Ups at The Park @ TLM - MASLD, Space 1 - CALD, Space 2 - Clinical Practice, Space 3 - HCV, Space 4 - PHHD, Space 5 - Early Career Hosted by Liver Fellow Network (LFN), Space 6
5:45-6:45 PM	Hepatology Associates Reception, Salon B <i>Sponsored by Mirum Pharmaceuticals</i>
7:00-8:00 PM	 Fellows' Reception at The National Building Museum
7:30-11:30 PM	Members' Reception at The National Building Museum <i>Sponsored by Madrigal Pharmaceuticals and Mirum Pharmaceuticals</i>

MONDAY, NOV. 10

9:45-10:45 AM	Meet-Ups at The Park @ TLM - Emerging Liver APP Awardees*, Space 1 - Emerging Liver Scholars (ELS) Awardees*, Space 2
12:30-2:00 PM	 Women's Networking Luncheon, Room 206 <i>Sponsored by Gilead Sciences and Madrigal Pharmaceuticals</i>
3:45-4:45 PM	Meet-Ups at The Park @ TLM - Hepatotoxicity, Space 1 - HBV, Space 2 - PLD, Space 3 - ACLF, Space 4 - Liver Cancer, Space 5 - Hepatology Associates, Space 6
6:30-7:30 PM	Diversity Reception, Marriott Marquis, Room: University of D.C.



By invitation only.



Ticket required.



AASLD members only.

ONE PROGRAM. COUNTLESS OPPORTUNITIES

Make the most of every opportunity to learn, network, and expand your knowledge at #TLM25 with this comprehensive guide. Download the mobile app for the most up-to-date information, as session details are current as of September 30.

FRIDAY, NOVEMBER 7

7 – 8 AM

Emerging Liver Advance Practice Provider Breakfast

Convention Center: Room 201, Level 2

Emerging Liver Scholar Breakfast

Convention Center: Room 206, Level 2

Patient Welcome Breakfast

Convention Center: Room 202

8 – 9:30 AM

Patient Engagement as a HABIT: Hope in Action – Breaking Barriers, Impactful Transitions

Convention Center: Room 209, Level 2

This engaging, interactive session kicks off with an advocate leader hosting “Excuses Bingo,” challenging participants to recognize and move past the barriers that hold us back. From there, we hear from a passionate leader in advocacy who shares a message of hope and empowerment. Leading medical experts then offer insights on hope through science, discussing breakthroughs across a spectrum of liver diseases. Finally, a diverse panel explores the shared struggles and victories across liver diseases, emphasizing impact, progress, and the unifying hope that connects us all. No matter the diagnosis, we move forward together – passing the baton toward a healthier future.

Basic Science Symposium: Endothelial Cells Occupy Center Stage in Liver Disease, Part 1 – Endothelial Cell Physiology and Heterogeneity

Convention Center: Ballroom A, Level 3

Presenters in this symposium focus on the varied functions of liver endothelial cells (ECs). ECs are specialized cells increasingly recognized for their heterogeneity and their key role in liver diseases and carcinogenesis. Recent advances in the understanding of EC function were made possible with refined isolation techniques coupled with multiomics studies. Speakers review emerging literature that defines liver ECs beyond their role as vascular barriers to critical mediators in various biological processes under physiologic and pathologic conditions.

8 AM – Noon

LLC Summit

Convention Center: Room 143, Level 1

8 AM – 5:30 PM

Postgraduate Course, Parts 1–4: A Lifetime of Liver Health

Convention Center: Hall A (General Session), Concourse Level

Achieving optimal health during our patients’ lifetimes is not something that should occur only after a provider recognizes liver disease. It is best understood and approached by incorporating the many facets of each patient’s history, genetics, environment, medications, and other exposures that change during their lives. The theme of this postgraduate course is to frame the way we approach patients and their liver care in the context of their current stage of life, while also considering past contributions as well as preparing for the future. As such, this course reframes information and teaching points – age, disease, surveillance, screening, extrahepatic contributions, and treatments all tied together as a continuum. The speakers present their approaches and complexities to each disease or intervention through the lens of a lifetime for each of the topics. Components include pregnancy and early life contributors, extrahepatic manifestations, alcohol use, and a full session on the aging patient. Taken together, this course intends to enhance the attendee’s understanding, approach, and planning for their individual patient’s needs to achieve optimal liver-centric health at all stages of their lives. The sessions include: Lifelong Age-Appropriate Screening, Surveillance and Therapeutic Choices; Extrahepatic Contributors to Liver Health Outcomes; The Die Is Cast at a Young Age – Early Life Determinants of Future Liver Health; and Liver Health in Older Adults.

Part 1 (8 – 9:45 AM): Lifelong Age-Appropriate Screening, Surveillance and Therapeutic Choices

Part 2 (10:45 AM – 12:30 PM): Liver Cancers – New Solutions for Old Problems

Part 3 (1:30 – 3:15 PM): The Die Is Cast at a Young Age: Early Life Determinants of Future Liver Health

Part 4 (3:45 – 5:30 PM): Liver Health in the Older Adults



FRIDAY, NOVEMBER 7

9:45 – 10:15 AM

SIG Abstract Highlights Station: Alcohol-associated Liver Disease (ALD)

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

Ask the Editorial Office

Convention Center: Science in the Park, Site B, Level 3

Have questions about ScholarOne or technical questions about submitting to Hepatology, Liver Transplantation, or Hepatology Communications? Come ask our Editorial Office staff!

9:45 – 10:45 AM

Emerging Livers Scholars Alumni Meet-Up

Convention Center: The Park @ TLM, Meet-Up #3, Level 2

Alumni and current awardees of the Emerging Liver Scholars program are welcome to join us for a meet-up in the park.

First Timers Meet-Up

Convention Center: The Park @ TLM, Meet-Up #1-2, Level 2

Welcome to your first experience of The Liver Meeting! Join us at the First Timer Meetup, a special event designed to welcome new attendees and help you make the most of your experience. This casual, friendly gathering is the perfect opportunity to:

- Meet fellow first-time attendees from around the world.
- Connect with esteemed AASLD members.
- Learn how to navigate the meeting and optimize your time.
- Ask questions and get insider tips.
- Begin building your professional network in hepatology.

Whether you're a trainee, early-career professional, or new to the field, this event will help you feel at home and ready to dive into everything The Liver Meeting® has to offer.

11 AM – 12:30 PM

Basic Science Symposium: Endothelial Cells Occupy Center Stage in Liver Diseases, Part 2 – Endothelial Cells in Acute Liver Injury and Inflammation

Convention Center: Ballroom A, Level 3

Presenters in this symposium focus on the varied functions of liver endothelial cells (ECs). ECs are specialized cells increasingly recognized for their heterogeneity and their key role in liver diseases and carcinogenesis. Recent advances in the understanding of EC function were made possible with refined isolation techniques coupled with multiomics studies. Speakers review emerging literature that defines liver ECs beyond their role as vascular barriers to critical mediators in various biological processes under physiologic and pathologic conditions.

Mapping the Transplant Journey: Perspectives from Pediatric and Adult Experience

Convention Center: Room 209, Level 2

The transplant journey is a complex and emotional process that differs across age groups while sharing critical milestones. Experts explore the unique challenges and experiences of pediatric and adult transplant patients from initial diagnosis to long-term survivorship. Through the lens of the transplant journey map, speakers connect real-life experiences to key stages in the transplant process, providing insights for patients, families, and care teams to navigate this life-changing path.

12:30 – 2 PM

Expert Perspectives on the Diagnosis and Proactive Management of Metabolic Dysfunction-Associated Steatohepatitis

Supported by: Novo Nordisk

Organized by: Med Learning Group

Convention Center: Room 147, Level 1

This interactive symposium will enhance knowledge of MASH diagnosis, risk stratification, and treatment. Expert-led sessions will review noninvasive diagnostic tools, guideline-driven staging, lifestyle interventions, and emerging therapies. Case-based discussions will engage learners in applying concepts to clinical scenarios and addressing real-world challenges in the diagnosis and proactive management of MASH.

FRIDAY, NOVEMBER 7

12:30 – 2 PM

The Capitol Challenge: Mastering PBC Care

Supported by: Intercept

Organized by: Medscape Education

Convention Center: Room 150, Level 1

Join us for a symposium on primary biliary cholangitis (PBC) designed to encourage the exchange of ideas between leaders in the field and attendees.

12:45 – 1:15 PM

HEPATOLOGY Cholestatic Liver Disease Special Issue

Convention Center: Science in the Park, Site B, Level 3

Come discuss the science behind the October special issue of Hepatology on cholestatic liver disease with Hepatology Associate Editor Dr. Cynthia Levy and Dr. Aliya Gulamhusein.

Abstract Highlights Station: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

1 – 2 PM

Friday Poster Presenters Hall Hour

Convention Center: Hall DE (Posters & Exhibits), Level 2

The following poster categories will be in the Poster Hall:

- o Alcohol-Associated Liver Diseases: Clinical and Experimental
- o Hepatitis B
- o Hepatitis C
- o MASLD/MASH - Experimental: Basic
- o MASLD/MASH - Experimental: Clinical

2 – 3:30 PM

Basic Science Symposium: Endothelial Cells Occupy Center Stage in Liver Diseases, Part 3 – Endothelial Cells in Chronic Liver Diseases

Convention Center: Ballroom A, Level 3

Presenters in this symposium focus on the varied functions of liver endothelial cells (ECs). ECs are specialized cells increasingly recognized for their heterogeneity and their key role in liver diseases and carcinogenesis. Recent advances in the understanding of EC function were made possible with refined isolation techniques coupled with multiomics studies. Speakers review emerging literature that defines liver ECs beyond their role as vascular barriers to critical mediators in various biological processes under physiologic and pathologic conditions.



Obesity and Addiction Medicine in Liver Disease: Translating Science into Practice, Part 1 – Understanding and Addressing Alcohol Use Disorder, Obesity, and Food Addiction

Convention Center: Room 207, Level 2

This course reviews timely topics regarding the management of alcohol use disorder (AUD), obesity, and food addiction. Experts highlight the striking behavioral and neurobiologic similarities between AUD and food addiction; key differences that impact clinical management; and the mechanisms underlying addiction in both contexts. Drawing on lessons from AUD treatment, the implications of food addiction in MASLD and alcohol-associated liver disease (ALD) are explored along with tips for effectively counseling patients on diet and lifestyle modifications. Using a case-based learning platform, presenters discuss multidisciplinary treatment strategies for both AUD and food addiction and explore integration of addiction medicine principles into hepatology clinical practice. Speakers further highlight the complexities of addiction management, addressing challenges such as relapse, patient adherence, and the role of emerging therapies in improving outcomes. Experts also provide an update on the evolving clinical definition of obesity and the latest advancements in pharmacological treatments, particularly in the context of MASLD and ALD, including the incorporation of novel anti-obesity medications into hepatology practice to optimize patient outcomes. An interactive workshop highlighting the role of motivational interviewing for effecting behavioral change in obesity and AUD management follows. Participants practice key techniques for engaging patients in meaningful conversations about lifestyle modifications and treatment adherence. Drawing from successful models in primary care, experts share practical strategies for overcoming patient resistance and enhancing motivation for long-term health improvements.

NOTE: Continuing education credits earned at this session count as group 2 credits toward the American Board of Obesity Medicine qualifications for certification via the CME pathway.

Transforming Lives in Alcohol-Associated Liver Disease: Early Detection, Equitable Treatment, and Inclusive Research Strategies *patient program*

Convention Center: Room 209, Level 2

This session on alcohol-associated liver disease (ALD) provides a comprehensive overview from both patient and physician perspectives, emphasizing early detection, equitable access to treatment, and inclusive research practices. The session includes a patient sharing their experiences, highlighting the physical and emotional challenges of living with ALD and the importance of support systems. Physicians discuss early detection, detailing diagnostic tools and the benefits of early intervention. They also address how disparities influence access to liver transplantation and clinical trial opportunities and propose strategies that center on equity. After the individual presentations, a panel of speakers answer questions from the audience and engage in a dialogue about the future directions in ALD detection, treatment, and research.

3:45 – 4:15 PM

Abstract Highlights Station: Acute on Chronic Liver Failure SIG

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.



FRIDAY, NOVEMBER 7

3:45 – 4:15 PM

Breakthrough Biomarkers in HBV

Convention Center: Science in the Park, Site B, Level 3

Come discuss the science behind the recent Hepatology review article on HBV Biomarkers with Associate Editor Dr. Jordan Feld.

4 – 5:30 PM

Basic Science Symposium: Endothelial Cells Occupy Center Stage in Liver Diseases, Part 4 – Endothelial Cells in Portal Hypertension, Liver Fibrosis, and Carcinogenesis

Convention Center: Ballroom A, Level 3

Presenters in this symposium focus on the varied functions of liver endothelial cells (ECs). ECs are specialized cells increasingly recognized for their heterogeneity and their key role in liver diseases and carcinogenesis. Recent advances in the understanding of EC function were made possible with refined isolation techniques coupled with multiomics studies. Speakers review emerging literature that defines liver ECs beyond their role as vascular barriers to critical mediators in various biological processes under physiologic and pathologic conditions.

Breaking Barriers: Confronting Stigma in Liver Disease and Supporting Vulnerable Communities

Convention Center: Room 209, Level 2

Stigma surrounding liver disease impacts patient outcomes, mental health, and access to care. Presenters explore the roots of stigma, with a focus on how misconceptions about liver disease affect care delivery and perpetuate health inequities. Special attention is given to the unique challenges faced by LGBTQ+ patients, who often encounter additional layers of bias and discrimination. The goal of this session is to empower health care clinicians, advocates, and stakeholders to foster equity and empathy in liver care for all communities by recognizing the impact of stigma on patient outcomes; developing inclusive practices for stigma-free care; and advocating for systemic change.



Obesity and Addiction Medicine in Liver Disease: Translating Science Into Practice, Part 2 – Interventions and Long-Term Management

Convention Center: Room 207, Level 2

Presenters open this session with a discussion of weight loss surgery and alcohol use. While bariatric surgery is a highly effective intervention for obesity, it is associated with an increased risk of developing alcohol use disorder (AUD) postoperatively. Speakers explore the mechanisms behind this phenomenon, including changes in alcohol metabolism and neurobiological adaptations following surgery, and share insights regarding identification of high-risk patients, implementation of preventive strategies, and providing postsurgical support to mitigate AUD risk of AUD in this vulnerable population. The second part of the session explores lifestyle interventions for MASLD and alcohol-associated liver disease (ALD). Lifestyle interventions, including diet and exercise, remain cornerstone treatments for MASLD and ALD, yet many patients struggle with adherence. Experts highlight practical guidance on prescribing and personalizing lifestyle modifications based on current evidence. Implementation of behavioral strategies, motivational techniques, and approaches to overcome common barriers to success by hepatologists can help their patients sustain long-term improvements in liver health. An interactive, case-based discussion follows. Participants engage in real-world case discussions, focusing on the intersection of MASLD, obesity, and AUD. Through a multidisciplinary approach, attendees work through complex patient scenarios, integrating behavioral, pharmacologic, and surgical interventions to enhance clinical decision-making skills.

NOTE: Continuing education credits earned at this session count as group 2 credits toward the American Board of Obesity Medicine qualifications for certification via the CME pathway.

5:30 – 6:30 PM

Special Interest Group (SIG) Meet-Ups #1

Convention Center: The Park @ TLM, Meet-Up #1-6, Level 2

Join your SIG Meet-Up, where you can connect with professionals who share your research and clinical interests! Enjoy light snacks, fun games, and great conversations in a relaxed, informal setting – perfect for networking and building new connections.

- o Meet-Up 1: Liver Cell Biology
- o Meet-Up 2: Liver Fibrosis and Cirrhosis
- o Meet-Up 3: Alcohol-associated Liver Disease
- o Meet-Up 4: Liver Transplantation & Surgery
- o Meet-Up 5: Portal Hypertension

7:30 – 9 PM



Awards & Honor Gala

Convention Center: Exhibit Hall A

7:30 – 9:30 PM

The Steatotic Liver Showdown: A Game Show on MASLD/MASH

Supported by: Boehringer Ingelheim Pharmaceuticals, Inc.

Organized by: Medscape Education

Marriott Marquis: Marquis Ballroom, Salon 6

Join us for a gameshow-style symposium on metabolic dysfunction-associated steatohepatitis (MASH) designed to encourage the exchange of ideas between leaders in the field and attendees.

SATURDAY, NOVEMBER 8

7 – 8 AM



SIG Leadership Breakfast

Convention Center: Room 206, Level 2

7 – 7:45 AM



MTE #1 Practical Aspects of Diagnosis and Management of Acute-on-Chronic Liver Failure

Convention Center: Room 140A, Level 1

Experts lead participants in case-based discussions of patients hospitalized with acute-on-chronic liver failure (ACLF). Topics include the application of evidence-based strategies for the advanced clinical management of patients with ACLF and critical illness, and the role of liver transplantation in this patient population.



MTE #2 Update on Management of Cholestatic Pruritus in Adults and Children

Convention Center: Room 140B, Level 1

Description: A hallmark symptom of cholestasis is pruritus, which can be severe and debilitating for many patients, significantly negatively impacting their quality of life. Experts present information focused on established and recently approved therapies to treat pruritus in cholestatic diseases. Speakers highlight a multistep approach to therapeutic options in pruritus, including alternative strategies in the settings of medication intolerance and difficult-to-treat pruritus.



MTE #3 The Heart-Liver Connection: Multidisciplinary Approach to Cardiovascular-Related Liver Disease

Convention Center: Room 144C, Level 1

Experts explore the complex interplay between cardiovascular and liver health, focusing on the challenges and opportunities in managing patients with cardiac-associated liver disease. Through a multidisciplinary lens, the session focuses on the impact of cardiovascular disease on end-stage liver disease; strategies for cardiovascular assessment in patients with advanced liver disease; and evidence-based approaches to optimize outcomes in this unique patient population. Speakers share insights to foster a collaborative framework for comprehensive patient care.



MTE #4 Programmed Cell Death: Mechanisms and Pathways

Convention Center: Room 149, Level 1

Subject matter experts compare the different types of cell death in homeostasis and liver injury, such as apoptosis, necrosis, autophagy, necroptosis, ferroptosis, and pyroptosis, among others. Topics include characterization of identification of the different modalities of cell death; the role of cell death in various liver diseases; signaling cascades and molecular mechanisms of cell death; and potential therapeutic strategies.



MTE #5 How to Select the Best Candidates for Early Liver Transplantation for the Diagnosis of Severe Alcohol-Associated Hepatitis

Convention Center: Room 154, Level 1

Experts provide information to help participants understand the current multidisciplinary approaches in identification of patients requiring consideration for early liver transplantation for severe alcohol-associated hepatitis and their clinical management. Topics include: prognostic models for predicting further decompensation versus recompensation; interpretation of phosphatidylethanol (PEth) testing; and approaches to reduce the likelihood of a return to alcohol use after liver transplantation.



MTE #6 Artificial Intelligence in Pediatric Hepatology and Pediatric Liver Transplantation

Convention Center: Room 158, Level 1

Explore the transformative role of artificial intelligence (AI) in pediatric hepatology and liver transplantation, highlighting how AI innovations are reshaping early diagnosis, risk stratification, and personalized treatment strategies for pediatric liver diseases. Experts review AI-driven advancements in noninvasive diagnostics, predictive analytics for disease progression, and optimizing donor-recipient matching in liver transplantation. Speakers also address the role of AI in improving posttransplant care, including graft survival prediction and early detection of complications. Emphasizing practical applications, ongoing challenges, and ethical considerations, this session demonstrates how AI can enhance decision-making, improve outcomes, and pave the way for precision medicine in pediatric liver care.



MTE #7 Approaching Challenges in the Prediction and Treatment of Intrahepatic Cholestasis of Pregnancy

Convention Center: Room 156, Level 1

Experts review updates in the field for the prognostication and management of intrahepatic cholestasis of pregnancy (ICP). Speakers lead a case-based discussion about challenging ICP cases and share approaches to management from ursodiol to ileal bile acid transporter (IBAT) inhibitor treatment. Topics include the association of chronic liver disease – including primary biliary cholangitis, hepatitis C, autoimmune liver disease, and cirrhosis – with the development of ICP, and the relevance of genetic testing for individuals with ICP.

7:45 – 8:15 AM

Abstract Highlights Station: Liver Transplantation and Surgery (LT&S) SIG

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.



SATURDAY, NOVEMBER 8

8 – 9:30 AM



American Association for the Study of Liver Diseases and the International Liver Transplantation Society Course, Part 1: Liver Transplant Oversight and Management Around the World

Convention Center: Room 202, Level 2

Gain insights into the current state of liver transplantation management worldwide. This segment provides updates on the Organ Procurement and Transplantation Network (OPTN) modernization project; explores international strategies for organ allocation (both deceased and living donations); and engages in a critical discussion of the advantages and challenges of posttransplant data reporting.

Artificial Intelligence: Transforming Liver Patient Care

Convention Center: Room 209, Level 2

Artificial intelligence (AI) affects multiple areas of our lives as clinicians, researchers, and patients. This session focuses on the rapidly evolving role of AI in liver disease care. Experts address (1) the potential role of AI in predicting disease progression, treatment response, and long-term outcomes; (2) limitations and challenges in the use of AI in the liver care setting; and (3) how AI is influencing communication between clinicians and their patients.

Beyond the Guidelines: Challenges and Controversies in the Management of Portal Hypertension

Convention Center: Ballroom B, Level 3

Subject matter experts review current challenges and controversies in the management of important complications of portal hypertension, including new approaches to refractory ascites, lower gastrointestinal bleeding due to portal hypertension, and the identification of recompensation. The program also includes a case-based expert panel discussion about the management of portal hypertension in the context of other complications such as liver cancer.

Cardiac and Liver Crosstalk in Fibrosis: Who Is the “Brains” of the Operation?

Convention Center: Room 146C, Level 1

Description: Cardiovascular disease is the leading cause of death among patients with MASH. The mechanisms by which liver fibrosis due to MASH promotes cardiovascular disease are not clear. Moreover, emerging data suggest that cardiac disease may promote liver fibrosis progression. In this session, speakers provide a clinical overview of the association between MASH-related fibrosis/cirrhosis and cardiovascular disease and dissect potential underlying mechanisms.

Hot Topics in Hepatitis B: New Clinical Tools for Hepatitis B Management

Convention Center: Room 146B, Level 1

Join the experts in this session to learn about highly relevant, clinical hot topic issues for hepatitis B management in 2025. Topics include quantitative HBsAg testing in clinical practice; HCC risk calculators; noninvasive testing for hepatic fibrosis; and metabolic dysfunction-associated steatotic liver disease in patients with HBV infection.

Our Environment and Liver Health: What Practitioners and Patients Need to Know

Convention Center: Room 146A, Level 1

Emerging public health data suggest that our environment — the surroundings or conditions in which we live, work, and play — may have substantial impact on the epidemiology of liver disease and the liver health of our communities. In some cases, research in this field may be conflicting, limited in scope, or difficult to translate into clinical practice leading to substantial uncertainty around patient counseling and messaging, and from patients themselves. Presenters summarize and interpret existing research on environmental exposures and liver disease and liver health, including on the development and progression of malignant (HCC and non-HCC primary liver cancers) and nonmalignant (hepatic steatosis, inflammation, fibrosis, and cirrhosis) liver disease.

Recent Advances in Primary Sclerosing Cholangitis Pathogenesis and Targets for Therapeutic Intervention

Convention Center: Room 207, Level 2

Presenters in this session expound on the current understanding of the pathogenesis, diagnosis, and treatment of primary sclerosing cholangitis (PSC). Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease leading to biliary fibrosis and cirrhosis. The etiology of PSC remains unclear. Recent studies demonstrate that senescence of ductular reactive cells and epithelial cells exacerbate cholestatic liver injury and activate fibrogenic myofibroblasts. With the development of new technologies such as single cell/nucleus RNA sequencing, the complexity of liver cell interactions and immunological responses are being characterized. Specific changes in farnesoid X receptor and Takeda G protein-coupled receptor 5 (TGR5) expression in cholangiocytes critically contribute to the pathogenesis of PSC. Treatment with nor-ursodeoxycholic acid (norUDCA) and nonsteroidal farnesoid X receptor agonist (cilofexor) are being tested in phase 3 clinical trials to assess improvement of liver function in patients with PSC. Novel strategies such as targeting myeloid cells or hepatic myofibroblasts are being developed to prevent/revert cholestatic fibrosis.

SATURDAY, NOVEMBER 8

8 – 9:30 AM

Steatotic Liver Disease: What You Need to Know, Part 1. Steatotic Liver Disease at the Crossroads – Bridging Alcohol-Associated Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the Era of Multimorbidity

Convention Center: Ballroom A, Level 3

Speakers delve into the intersections between alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on how multimorbidity – such as obesity, diabetes, and cardiovascular disease – complicates diagnosis, management, and prognosis. Experts discuss the shared and unique pathophysiological mechanisms, the role of genetic and behavioral risk factors, and the importance of a multidisciplinary approach to patient care.

9:45 – 10:15 AM

Abstract Highlights Station: Liver Cancer SIG

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

9:45 – 10:45 AM

American Association for the Study of Liver Diseases and Society on Liver Disease in Africa Community Conversation: Drug-Induced Liver Injury in Africa

Convention Center: Room 206, Level 2

This interactive, joint AASLD and Society on Liver Disease in Africa (SOLDA) community conversation explores the global epidemiology of DILI and regional differences in its etiology. Needs associated with DILI and associated registries are identified. Through case presentations, panelists illustrate unique features of etiologies of DILI in Africa and highlight differences in diagnostic strategies and management. Presenters also review DILI survey data from Africa and identify DILI-related research gaps. The session aims to formulate strategies to overcome DILI management challenges and advance DILI-related research in Africa.



American Association for the Study of Liver Diseases and the International Liver Transplantation Society Course, Part 2: Substance Use Disorders

Convention Center: Room 202, Level 2

Delve into the complexities of liver transplantation among patients with alcohol-associated liver disease (ALD). Topics include the clinical and logistical resources required, ethical considerations – especially in living donor contexts – and the critical role of relapse prevention and psychosocial support in long-term outcomes.

American Association for the Study of Liver Diseases and Taiwan Association for the Study of the Liver Community Conversation: Hepatocellular Carcinoma Surveillance, Challenges, and Solutions

Convention Center: Room 201, Level 2

This joint AASLD and the Taiwan Association for the Study of the Liver (TASL) session aims to: (1) continue the collaborative relationship between TASL and AASLD; (2) share experiences and contributions to HCC surveillance in Taiwan with AASLD members; (3) facilitate young investigators' communication with AASLD members to foster future collaboration; and (4) encourage TASL members to attend The Liver Meeting to learn from and connect with scholars from around the world.

Diversity Meet-Up

Convention Center: The Park @ TLM, Meet-Up #3-4, Level 2

Join AASLD's Diversity, Equity, and Inclusion Committee for this social networking meetup at the Park Meet at The Liver Meeting. Meet and engage with other attendees interested in diversity and inclusion issues.



Special Interest Groups (SIG) Business Meetings

- o **ALD** | **Convention Center: Ballroom A, Level 3**
- o **Cholestatic Liver Disease** | **Convention Center: Room 207, Level 2**
- o **Hepatitis B** | **Convention Center: Room 146B, Level 1**
- o **Liver Fibrosis** | **Convention Center: Room 146C, Level 1**
- o **Public Health** | **Convention Center: Room 146A, Level 1**
- o **Portal Hypertension** | **Convention Center: Ballroom B, Level 3**

Meet-Ups

Convention Center: The Park @ TLM, Meet-Up #1-6, Level 2

- o Meet-Up 1: **AASLDF Research & Career Development Awardee**
- o Meet-Up 2: **Primary Biliary Cholangitis (PBC) Patient Meet-Up**

This meet-up fosters meaningful interaction between the patient community with health care clinicians focused on those affected by primary biliary cholangitis (PBC).

Stump the Hepatologist

Convention Center: Salon GH, Level 1

The Stump the Hepatologist session demonstrates the "art" behind the science of working through a differential diagnosis. Through live interactions with case presenters, hepatology experts work through interesting and challenging cases, voicing their thought process as the case unfolds. Participants witness how experts in the field, using their knowledge base, break down and narrow their differential diagnosis to solve the case. Following determination of the final diagnosis, each case presenter provides a brief synopsis of relevant literature.



SATURDAY, NOVEMBER 8

11 AM - 12:30 PM



American Association for the Study of Liver Diseases and the International Liver Transplantation Society Course, Part 3: Expanding the Donor Pool Through Perfusion Technology

Convention Center: Room 202, Level 2

Explore the innovative role of machine perfusion technologies in expanding the liver donor pool. Presenters highlight the latest in preservation platforms, therapeutic interventions during perfusion, and the use of viability markers to optimize graft success.

Applications of Real-World Data in Clinical Practice

Convention Center: Room 146A, Level 1

Presenters explore commonly encountered clinical scenarios where practice patterns are variable, and consensus is often lacking on the appropriate application of guidelines. Experts offer insights from real-world experience and large-scale data to generate consensus on the best clinical practices in the following scenarios: applying portal hypertension guidance to individual patients; improving surgical risk stratification; rethinking spontaneous bacterial peritonitis prophylaxis; and optimizing use of albumin and terlipressin.

Best of the Liver Fellow Network

Room 146C, Level 1

Speakers highlight the offerings of the AASLD Liver Fellow Network (LFN) with presentations of the most impactful posts by content creators in each core series: Clinical Pearls, Pathology Pearls, Evidence Corner, the Why? Series, and Back to Basics. Each presentation is followed by a discussion moderated by LFN leads and faculty chairs with the goal of critically appraising the literature highlighted in the presentations (Evidence Corner and the Why? Series) and discussing challenges and pearls in the diagnosis and management of patients with liver disease (Clinical Pearls, Pathology Pearls, and Back to Basics). The session aims to improve attendees' understanding of the strengths and limitations of the presented literature and greater knowledge regarding the multitude of diagnostic and management options for patients with liver disease.

Multimic Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease

Convention Center: Ballroom B, Level 3

Presenters review how genomic, transcriptomic, and other omic technologies can help us understand the causes and inform treatments for MASLD. Experts elaborate on integrative multimic analyses, genetic subtyping and risk stratification, phenotypic clustering, microbiome analyses, and metabolic and genetic metabolomic profiles as they relate to MASLD.

The Editors Cut: Clinical Studies

Convention Center: Ballroom A, Level 3

This session comprises a critical discussion of the most notable and influential clinical research papers published in HEPATOLOGY in the past year by a team of Associate Editors from the journal HEPATOLOGY. Associate Editors Sumera Ilyas, Jennifer Lai, and Manal Abdelmalek appraise the most cutting-edge, game-changing clinical science research literature. A panel discussion with the speakers, Editor-in-Chief Gregory Gores, and Associate Editor Jacqueline O'Leary highlights the clinical impact of selected papers and key challenges and opportunities in the field.

The Road to Cure and Elimination of Viral Hepatitis B and C: Breaking Barriers for Patients and Communities

Convention Center: Room 209, Level 2

The World Health Organization (WHO) has established criteria for elimination of hepatitis B and hepatitis C as public health threats by 2030. Most countries, however, are not on track to meet these WHO goals. Many patients with HBV and/or HCV infection do not have access to treatment, vaccination, or harm reduction efforts. Presenters address the main barriers to viral hepatitis elimination from patient and community perspectives, and strategies to overcome them.

Therapeutic Choices in Hepatology, 2025

Convention Center: 146B, Level 1

In this case-based program, presenters provide updates on key topics in general hepatology including: (1) steatotic liver disease, with emphasis on the treatment of MASH and considerations surrounding diagnosis and management of MetALD; (2) hepatitis B management based on the AASLD 2025 guidelines; and (3) primary sclerosing cholangitis, particularly addressing screening, use of pharmacotherapy, and drug development. Cases are used to give clinicians a real-world approach to management of these common liver diseases.

Update on Hepatitis C Elimination in 2025

Convention Center: Room 207, Level 2

In this joint session with the European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis, experts review and discuss the most updated information on hepatitis C elimination in the United States and other countries. Presenters explore obstacles to execution of hepatitis C elimination plans and strategies to overcome these challenges.

Wait Wait...Don't DILI!

Convention Center: Ballroom C, Level 3

Join in the fun with the 3rd iteration of the popular (standing room only in 2024) and only (thank goodness) hepatotoxicity-themed game show at The Liver Meeting. The style and format of this workshop is loosely based on the NPR game show, "Wait wait...Don't Tell Me!". The Hepatotoxicity Special Interest Group has assembled a panel of experts to address cutting-edge topics in DILI and mechanisms of hepatotoxicity. Speakers present in a "speed data" format, with the majority of time left for discussion and engagement with panelists and the audience. Speakers are introduced by ridiculous limericks anchored in the topic of the presentation rather than extensive CVs. The session features audience participation in a competition to win a unique AASLD Wait Wait...Don't DILI! mug.

SATURDAY, NOVEMBER 8

12:30 - 1 PM



AASLD Leadership Luncheon

Convention Center: Room 206, Level 2

12:30 - 2 PM

A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration

Supported by: Madrigal Pharmaceuticals

Organized by: AKH, Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC

Convention Center: Room 151, Level 1

Join our experts as they discuss practical aspects of integrating liver-directed therapy for the treatment of MASH. Listen as they discuss real-world successes and challenges with using THR-B agonists and GLP-1RAs. Catch up on the latest data on noninvasive testing and other treatments in late-stage development.

Connecting the Clues: Lung and Liver Considerations in Diagnosing Alpha-1 Antitrypsin Deficiency

Supported by: Takeda

Organized by: Medscape Education

Convention Center: Room 150, Level 1

Join us for a symposium on alpha-1 antitrypsin deficiency (AATD) designed to encourage the exchange of ideas between leaders in the field and attendees.



Masterclass Meet-Up

Convention Center: The Park @ TLM, Meet-Up #1, Level 2

Raising the Bar: Innovations in PBC Care

Supported by: Gilead Sciences, Inc.

Organized by: Clinical Care Options, LLC

Convention Center: Room 152, Level 1

This interactive symposium will feature expert perspectives on advancing the standard of care for individuals living with PBC. Discussion will focus on strategies aimed at achieving normalization of biochemical markers, alleviating symptom burden, and exploring the potential role of new and emerging therapies in improving patient outcomes.

Toward Functional Cure in Chronic HBV: Monitoring, Serological Markers, and Evolving Therapy

Supported by: GSK

Organized by: PVI, PeerView Institute for Medical Education

Convention Center: Room 147, Level 1

Join PeerView and leading experts for an engaging symposium on advancing functional cure in chronic hepatitis B. Gain insights on how qHBsAg testing sharpens decision-making, explore evolving antiviral therapies, and apply guideline-based strategies to monitor treatment success and prevent complications. Elevate your HBV practice and improve outcomes for your patients!

12:45 - 1:15 PM

Abstract Highlights Station: Clinical Practice SIG

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

How I Utilize Palliative Care

Convention Center: Science in the Park, Site B, Level 3

How do you study palliative care? Come discuss the science behind the recent Hepatology Communications article on the "Surprise Question," a clinician-based prognostication tool initially developed to identify patients who may benefit from palliative care interventions with Dr. Nneka Ufere.

12:45 - 1:30 PM



MTE #8 The Role of Hepatorenal Syndrome-Acute Kidney Injury Treatment in Acute-on-Chronic Liver Failure Patients Under Consideration for Transplant

Convention Center: Room 140A, Level 1

Experts lead participants in a discussion of the complexities, risks, and benefits of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) in patients with acute-on-chronic liver failure being considered for liver transplantation. Topics include treatment strategies, implications for waitlist prioritization, and use of terlipressin.



MTE #9 Artificial Intelligence in Clinical Practice and Clinical Research in Liver Diseases

Convention Center: Room 140B, Level 1

Presenters focus on the transformative potential of artificial intelligence (AI) in the context of liver diseases. Key topics include: AI-driven advancements in clinical research such as natural language processing for unstructured clinical data analysis; predictive modeling for patient outcomes; and multimodal data integration for comprehensive patient profiling. Speakers discuss clinical applications and highlight AI tools for decision support, ambient scribes, and automated message drafting to improve patient communication. Experts provide practical examples and actionable insights to enable participants to effectively integrate AI into their clinical and research workflows.



SATURDAY, NOVEMBER 8

12:45 - 1:30 PM

MTE #10 Drug-Induced Liver Injury from Herbal and Dietary Supplements in 2025: New Kids on the Block

Convention Center: Room 144C, Level 1

Speakers provide updates on novel herbal and dietary supplements that may potentially cause liver injury, including but are not limited to green tea extracts, curcumin/turmeric, ashwagandha, kratom, black cohosh, garcinia cambogia, and red yeast extract. Topics include specific signatures and patterns of liver enzymes associated with liver injury due to ingestion of selected herbal compounds and over-the-counter medications, and compounds that are considered to present minimal risk for DILI.

MTE #11 Innate-Adaptive Immune Crosstalk in Hepatic Fibrosis and Inflammation

Convention Center: Room 149, Level 1

Experts explore the dynamic interactions between the innate and adaptive immune systems in the context of liver fibrosis and inflammation and provide insights into cutting-edge research and strategies for addressing liver fibrosis and associated inflammatory conditions. Key areas of focus include: (1) immune system roles — how innate immune cells (e.g., macrophages, dendritic cells) and adaptive immune components (e.g., T cells and B cells) communicate and influence hepatic tissue responses; (2) mechanisms of crosstalk — signaling pathways, cytokines, and cellular interactions that drive fibrosis and chronic liver inflammation; and (3) clinical implications — how immune crosstalk contributes to disease progression and identification of potential therapeutic targets to modulate the immune response and treat liver disorders.

MTE #12 The Use of Point-of-Care Ultrasonography in Hepatology

Convention Center: Room 154, Level 1

Point-of-care ultrasonography (POCUS) is widely considered the “new stethoscope.” Speakers review the uses of liver POCUS and discuss how POCUS can help when evaluating a patient during a hepatology consult. Experts present case studies as examples of how liver POCUS helped them define or change a diagnosis and answer questions about the use of liver POCUS.

MTE #13 Parenteral Nutrition-Associated Liver Disease in Pediatrics: Recent Advances in Pathogenesis and Management

Convention Center: Room 158, Level 1

Parenteral nutrition (PN) provides lifesaving nutrition to infants and children unable to feed enterally. Its use, however, may be complicated by parenteral nutrition-associated liver disease (PNALD). Experts present the pathogenesis of PNALD; PN improvements over the past few decades for hepatic protection; and current research updates in PNALD.

1 - 2 PM

AASLD Annual Business Meeting

Convention Center: Room 206, Level 2

Saturday Poster Presenters Hall Hour

Convention Center: Hall DE (Posters & Exhibits), Level 2

The following poster categories will be in the Poster Hall:

- o Advanced Practice Providers (NP, PA, RN, PharmD, etc.)
- o Diagnostics and Biomarkers – MASLD and MASH
- o Health Disparities/Health Equity Research
- o Hepatitis – Other Infections
- o MASLD/MASH –Epidemiology and Natural History, Prevention and Outcomes
- o MASLD/MASH –Treatment: Non-pharmacologic
- o Portal Hypertension and Other Complications of Cirrhosis

2 - 3:30 PM

American Association for the Study of Liver Diseases and the International Liver Transplantation Society Course, Part 4: Contemporary Challenges

Convention Center: Room 202, Level 2

Experts address current and emerging challenges in liver transplantation, including recurrence of metabolic syndrome post-transplant, pediatric transplantation complexities, and the utility of posttransplant biomarkers. The potential of paired exchange to broaden donor options is also examined.

Hepatitis C Management in Unique and Key Populations

Convention Center: Room 207, Level 2

Experts examine and discuss the latest information regarding the management of special populations with chronic HCV infection. The unique and key populations addressed in the session include men who have sex with men, transgender individuals, persons in carceral facilities, pregnant individuals, children, and people who inject drugs.

Managing the ABCs of Liver Disease

Convention Center: Room 146A, Level 1

Presenters in this session review the challenges in managing patients with various types of liver disease that are commonly consults for the hepatologist. Topics include viral hepatitis, iron overload, steatotic liver disease, and hepatocellular carcinoma.

Navigating the Health Care Maze: Empowering Patients with Information and Tools

Convention Center: Room 209, Level 2

Presenters focus on empowering patients to effectively navigate the health care system. Topics include debunking common myths, utilizing practical tools, and understanding the differences between alternative, complementary, and integrative medicine.

SATURDAY, NOVEMBER 8

2 - 3:30 PM

New Frontiers in Acute-on-Chronic Liver Failure: Bridging Gaps and Pioneering Solutions

Convention Center: Ballroom B, Level 3

The Acute-on-Chronic Liver Failure (ACLF) Special Interest Group presents current clinical and research gaps pertaining to the study and care of patients with ACLF. The introductory presentation prompts further discussion on 4 distinct topics focused on: (1) outstanding care gaps in critically ill patients with ACLF; (2) the role of novel statistical methods in ACLF diagnosis and prognostication; (3) designing clinical studies in ACLF; and (4) pathways to therapeutic advancements in ACLF. The session concludes with a panel discussion.

Sexual Dimorphism in the Liver

Convention Center: Room 146B, Level 1

Presenters review recent advances in our understanding of sexual dimorphism in the liver and its contribution to liver growth, metabolism, and disease. The concepts covered by the thought leaders and content experts include the effect of sex hormones on hepatocyte proliferation and sex-specific differences in metabolic demands. They also cover concepts of sexually dimorphic responses in specific chronic pathologies including MASLD and HCC. Sex as a biological variable is often overlooked, which can result in delayed or inappropriate treatment. However, because the liver responds differently in males and females, this important variable needs to be considered both in experimental design and interpretation.

Steatotic Liver Disease: What You Need to Know, Part 2. Dual Threats – Advancing Research and Care in Steatotic Liver Disease

Convention Center: Ballroom A, Level 3

Presenters in this session focus on advancing research and therapeutic strategies for steatotic liver disease (SLD), with an emphasis on MASLD and its subtypes. Discussions highlight lifestyle interventions, pharmacologic treatments, and global health perspectives. Experts address the challenges of implementing evidence-based care and explore innovations that improve outcomes for diverse patient populations.

The Tumor Microbiome–Microenvironment Nexus: Unraveling Therapeutic Horizons

Convention Center: Room 146C, Level 1

Emerging evidence has shed light on the complexity of the gut microbiome and its influence on the tumor immune microenvironment, tumorigenesis, and therapeutic responses. Sequencing studies have examined the differential microbiota composition between healthy individuals and patients with cirrhotic liver disease. Recent studies have shown the influence of the gut microbiome on liver cancer development and progression. Thereby, the gut microbiome represents a potential target for therapeutic intervention, and its composition may potentially serve as a predictive biomarker for enhanced responses to immunotherapy. In this session, experts review recent advances in our understanding of: (1) the role of the gut microbiome in influencing liver cancer tumorigenesis and progression; (2) the effect of the gut microbiome on immunotherapy sensitivities; (3) the relationship of the gut microbiome with the immune system; and (4) the development of novel therapeutics.

3:45 - 4:15 PM

Abstract Highlights Station: HepTox SIG

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

Meet the New Liver Transplantation Editors and Pitch Your Article!

Convention Center: Science in the Park, Site B, Level 3

Come discuss the editorial team's plan for the next 5 years of LT and pitch your article ideas to the Editors-in-Chief and Deputy Editors!

3:45 - 4:45 PM

AASLD/KASL: Innovative Ideas to Change Practice

Convention Center: 201, Level 2

Continuing the successful AASLD-KASL collaboration since 2023, this session highlights practice-changing innovations in hepatology from leading researchers in the U.S. and Korea. Topics include the application of artificial intelligence for non-invasive assessment of liver fibrosis in patients with MASLD, the use of speech pattern analysis as a digital biomarker for detecting hepatic encephalopathy, clinical data on autologous bone marrow-derived mesenchymal stem cell transplantation for liver cirrhosis, and AI-powered tools that synthesize clinical guidelines to support real-time decision-making. A panel discussion will follow to explore the clinical impact, implementation challenges, and global relevance of these emerging technologies.

Academic Debate: Is There a Role for Living Donor Liver Transplant in Adult Patients in the Age of Machine Perfusion?

Convention Center: Ballroom C, Level 3

Organ access continues to evolve and is a primary challenge in caring for patients with chronic liver disease. Liver transplant indications in adults have changed over the past decade with the rise of MASLD and the decline of hepatitis C. The landscape of organ availability has concurrently shifted, including national policies, expansion of donor criteria, machine perfusion, and living donor transplant. To highlight the role of living donor transplant in this evolving context, this academic debate session features teams of hepatology trainees and practicing hepatologist debating the pros and cons of the question: Is there a role for living donor liver transplant in adult patients in the age of machine perfusion? The pro position argues that living donor transplant is effective and relevant; the con position argues that living donor transplant will no longer be needed. Debaters, judges, and attendees grapple with opposing scientific, societal, individual, and financial viewpoints on this timely issue.



SATURDAY, NOVEMBER 8

3:45 – 4:45 PM



American Association for the Study of Liver Diseases and the International Liver Transplantation Society Course, Part 5: The Future of Liver Transplantation

Convention Center: Room 202, Level 2

Look ahead to the transformative possibilities in transplant medicine. Presenters explore the expanding role of liver transplantation in oncology, developments in xenotransplantation, and the integration of deep machine learning to predict outcomes and enhance decision-making.

Clinician and Medical Educators Meet-Up

Convention Center: The Park @ TLM, Meet-Up #1, Level 2

Clinician educators and those with an interest in medical education are invited to connect with your fellow educators at this meetup. Gather for an hour of informal networking with other TLM attendees pursuing a clinician educator career path to share with colleagues, get and give support, and learn from your peers.

HepatoTalk: Navigating Difficult Conversations Between Clinicians, Patients, and Families

Convention Center: Salon GH, Level 1

This interactive session provides clinicians a unique opportunity to both learn and practice evidence-based skills for handling tough conversations they may experience with patients and families. Presenters first review evidence-based approaches for common communication challenges (e.g., delivering serious news, handling uncertainty, responding to emotions), discuss key phrases, and model ideal and less-than-ideal encounters. Participants then break into small groups to practice core serious illness communication skills using standardized patient encounters and receive in-the-moment feedback from experts. Presenters lead a group reflection to conclude the session.

Level-Up Your Electronic Health Record Use: Practical Strategies to Optimize Hepatology Practice and Research

Convention Center: Room 206, Level 2

This community conversation aims to empower hepatology practitioners to optimize their use of the electronic health record (EHR) for improved clinical workflows and research capabilities. Key topics include live demonstrations of hepatology-specific EHR workflows; practical tips and best practices for Epic and Oracle Health EHRs; and an introduction to Epic's SlicerDicer tool for clinical research. An interactive hands-on workshop follows the presentations, allowing participants to "choose their own adventure" at designated stations where they can explore EHR tools, receive guidance from presenters, and interact with Epic and Oracle Health experts. By the end of the session, participants will have actionable strategies to implement and tailor EHR tools locally and across health systems.

Patient Meet-Up: Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Sponsored by: Madrigal Pharmaceuticals

Convention Center: The Park @ TLM, Meet-Up #2, Level 2

This unique meetup fosters meaningful interaction between the patient community and health care practitioners focused on those affected by MASLD/MASH.

Special Interest Groups (SIG) Business Meetings

- o **ACLF** | **Convention Center: Ballroom B, Level 3**
- o **Clinical Practice** | **Convention Center: Room 146A, Level 1**
- o **Hepatitis C** | **Convention Center: Room 207, Level 2**
- o **Liver Cancer** | **Convention Center: Room 146C, Level 1**
- o **Liver Cell Biology** | **Convention Center: Room 146B, Level 1**
- o **MASLD** | **Convention Center: Ballroom A, Level 3**

The Liver Fellow Network Presents: Ask Me Anything About Transplant Hepatology Training and Early Career

Convention Center: Room 143, Level 1

This interactive session includes panelists representing advanced fellows and academic faculty who are available to answer participants' questions regarding diverse pathways for hepatology training and research opportunities as well as the ins and outs of finding training opportunities and employment. Discussion topics include advanced and transplant hepatology fellowships; finding a gastrointestinal (GI) fellowship; GI clinical research fellowships; hepatology training as an international medical graduate; American Board of Internal Medicine's fast-track hepatology fellowship; hepatology training before GI fellowship; informatics and hepatology; finding a niche; finding a mentor; and finding a hepatology job.

5 – 6 PM

President's Welcome and President's Choice Lecture: The Best of Times and The Worst of Times – Hope and a Plan for Action

Convention Center: Hall A, General Session, Concourse Level

America's dominance in medical research over the last few decades has been remarkable, with exponentially increasing advances that have saved millions of lives and reduced suffering. Yet dark clouds are now around us. NIH support for basic and translational research in US research universities is under attack. And even for breakthroughs that have happened, our broken health care system is not always able to deliver therapies for conditions like sickle cell anemia and hepatitis C. But there is hope. Americans are waking up to the fact that these attacks on medical research are not what they want for themselves and their families, and creative solutions are being developed to deliver cures to those who need them.

SATURDAY, NOVEMBER 8

6 – 7:30 PM

Exhibit Hall Opening Reception

Sponsored by: *Mirum Pharmaceuticals*

Convention Center: Hall D (Exhibits), Level 2

Description: Begin your experience at The Liver Meeting® with an evening of mingling, refreshments, and a warm welcome from AASLD as you explore the Exhibit Hall. This casual gathering provides the opportunity to meet new colleagues and hear from industry leaders.

7:30 – 9:30 PM

MASLD and Cardiometabolic Syndrome: The Dream MDT team!

Supported by: *Perspectum Ltd*

Organized by: *HealthProMatch*

Marriott Marquis: Marquis Ballroom Salons 6

MASLD, Obesity, Cardiometabolic Syndrome, T2DM are all overlapping yet distinct diseases. Follow a patient in real time from primary to tertiary care. Challenge the experts in hepatology, cardiology and obesity medicine as they debate the latest research and missed opportunities along the patient's journey: Juggle polypharmacy, lifestyle interventions, biomarkers, multimodal imaging. Interactive Evening Symposium. Dinner and Refreshments provided.

7:30 – 8:30 PM

PRIDE Reception

Sponsored by: *Gilead Sciences*

Marriott Marquis: University of DC and Catholic University

Join us for AASLD's Pride Reception, hosted by the LGBTQ+ Committee. This event offers a welcoming space for LGBTQ+ members and allies to connect, build community, and celebrate the values of inclusion and belonging within the hepatology field. Come share experiences and strengthen the spirit of connection that supports all members of our professional community.

HONOR THE PAST, SUPPORT THE FUTURE

**VISIT THE WALK OF HONOR LOCATED
OUTSIDE HALL A OF THE CONVENTION CENTER.**



SUNDAY, NOVEMBER 9

7 – 7:45 AM

MTE #15 Integrated Alcohol-Associated Liver Disease Clinics: How to Start and Lessons Learned

Convention Center: Room 140A, Level 1

Experts provide a primer on how to start, organize, and refine an integrated, multidisciplinary alcohol-associated liver disease (ALD) clinic. Topics addressed include creation of a business plan and troubleshooting potential pitfalls in running an integrated ALD clinic.

MTE #16 Rise of Machines: 101 for Hepatologists

Convention Center: Room 140B, Level 1

Experts provide a case-based, in-depth tutorial on machine perfusion, donor management, and outcomes of liver transplantation using organs procured from donation after circulatory death (DCD). Topics include an overview of the various techniques of machine perfusion for DCD liver allografts, including programmatic costs; and short-term and long-term impacts of machine perfused DCD liver allografts on patient-survival, graft survival, and biliary complications.

MTE #17 Refractory Immune-Mediated Liver Injury from Checkpoint Inhibitors: When to Bring Out the Big Guns?

Convention Center: Room 144C, Level 1

Hepatologists are often consulted by our oncology colleagues when patients develop immune-mediated liver injury from checkpoint Inhibitors (ILICI) that are steroid refractory and resistant. Speakers in this session discuss the exploratory second line and third-line treatment options that have been successfully used in case series, case reports, and in other immune-mediated adverse events such as colitis, pneumonitis, dermatitis, and myocarditis.

MTE #18 Liver Regeneration Fibrosis: The Role of Liver Regeneration in Both Fibrosis Progression and Regression

Convention Center: Room 149, Level 1

Explore the dual role of liver regeneration in the context of hepatic fibrosis. Experts provide a comprehensive discussion of the interplay between liver regeneration and fibrosis with a focus on therapeutic approaches to manage chronic liver disease. Topics include: (1) mechanisms of liver regeneration examining the molecular and cellular processes driving the liver's regenerative capacity; (2) fibrosis progression focused on how dysregulated regeneration can contribute to the accumulation of fibrotic tissue and chronic liver damage; (3) fibrosis regression exploring how effective liver regeneration can reverse fibrotic changes and restore normal liver function; and (4) the therapeutic implications of implementing strategies to modulate liver regeneration for promoting fibrosis resolution while minimizing the risk of further progression.

MTE #19 Ethical Dilemmas in Transplant: Who Gets the Liver?

Convention Center: Room 154, Level 1

Experts present 3 cases involving ethical dilemmas in the transplant setting and review options on how clinicians should proceed. Cases address topics on transplantation, who should be listed for transplant (i.e., prior history of drug use or alcohol use disorder), and what to do when a patient goes to another country for transplantation.

MTE #20 Career Development and Pathways in Hepatology and Informatics

Convention Center: Room 158, Level 1

This session explores the ways that practicing hepatologists and trainees can incorporate clinical informatics into their careers. Discussion leaders cover the breadth of informatics engagement including: how to obtain additional training and education in informatics; learning how to use and create tools to optimize electronic health record workflows; participation in system-level informatics governance; and clinical research and quality improvement using electronic health record data and informatics tools. The session also addresses how to get involved in clinical informatics fellowships, pathways to clinical informatics board certification, and career options for the hepatologist with an interest or expertise in clinical informatics.

7:45 – 8:15 AM

Abstract Highlights Station: CALD

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

SUNDAY, NOVEMBER 9

8 – 9:30 AM

Basic Science Workshop, Ribonucleic Acid Nanomedicine: Reprogramming Cells to Transform Liver Outcomes, Part 1 – Cutting-Edge Tools for Liver Gene Editing

Convention Center: Room 207, Level 2

RNA nanomedicine has emerged as a groundbreaking approach for safely delivering genetic instructions into target cells, enabling their reprogramming without degradation. Its significance was underscored during the COVID-19 pandemic with the successful deployment of mRNA-based vaccines formulated using lipid nanoparticles. These nanoparticles, available in various formulations, act as carriers to transport RNA directly into target cells for therapeutic action. Patisiran and lumasiran – 2 FDA-approved RNA interference (RNAi) agents delivered via lipid nanoparticles (RNA nanotherapeutics) – exemplify this new generation of targeted therapies. These treatments have significantly reduced the need for liver transplantation in patients with genetic conditions such as amyloidosis and hyperoxaluria. Consequently, referrals for liver transplantation due to these metabolic disorders have dramatically declined, highlighting the transformative potential of RNA nanomedicine in clinical practice. In this workshop, experts review the transformative world of RNA nanomedicine; explore its role in delivering genetic instructions with unparalleled precision; discover how advancements in lipid nanoparticle (LNP) formulations are enabling breakthrough therapies; and gain insights into the latest clinical applications that are reshaping treatment paradigms, such as reducing the need for liver transplantation in genetic and metabolic disorders.

Career Development Workshop

Convention Center: Salon GH, Level 1

This workshop aims to increase interest in hepatology for early learners and expose them to the different training and career options. Presenters also aim to promote successful career growth for those already engaged in a hepatology career by discussing techniques on how to build successful practice models and leadership skills. Attendees can learn from successful hepatology faculty in a variety of career pathways, initially through presentations, followed by a panel discussion. Time is allocated for individual questions with faculty presenters following the workshop.

Cellular Signaling and Metabolic Regulation in Chronic Liver Disease

Convention Center: Room 146A, Level 1

This session explores the intricate signaling pathways and metabolic networks that govern liver injury, repair, and chronic disease progression. Presentations will cover hepatocyte-stellate cell interactions, nuclear receptor signaling, autophagy zonation, and the molecular regulation of regeneration and fibrosis. Through multiomics and tissue-specific analyses, these studies illuminate how dysregulation of cellular communication and metabolism contributes to conditions such as steatohepatitis, fibrosis, sarcopenia, and Type II diabetes.

Distinct Pathways, Shared Progress: Metabolic/Genetic Disorders & Biliary Physiology

Convention Center: Room 145, Level 1

This session highlights innovations from molecular mechanisms to drug development and clinical trials in biliary physiology and genetic and metabolic conditions. This session will spotlight cholangiocyte biology from scaffolding to repair. Gain insight into mechanisms and therapeutics for A1AT deficiency, Wilson Disease, and hemochromatosis.

Global Perspectives on Acute Liver Failure

Convention Center: Room 146B, Level 1

Gain insights into the global aspects of acute liver failure by exploring the epidemiology, therapies, and preventive approaches in various regions of the world, as well as differentiating acute liver failure from acute-on-chronic liver failure. Learn from leading experts from various regions of the world who present on specific aspects of acute liver failure using a case-study approach. This session is co-endorsed by our sister societies: the Latin American Association for the Study of the Liver, the Asian Pacific Association for the Study of the Liver, the European Association for the Study of the Liver, and the Society on Liver Disease in Africa.

Hepatocellular Carcinoma as a Chronic Disease: Managing Ongoing Surveillance, Multiple Treatments, Symptoms, and Quality of Life

Convention Center: Room 209, Level 2

Explore hepatocellular carcinoma (HCC) through the lens of living with a chronic disease. From the time of HCC diagnosis, most patients are faced with undergoing lifelong surveillance with regular multiphasic imaging studies and, often, undergoing multiple rounds of treatment including different types of locoregional and systemic therapies. This exacts a substantial toll on quality of life, limits the ability to participate in work and family-related activities, and imposes great symptom, psychological, physical, and financial burdens. Speakers focus on the importance of patients preparing for the long-term trajectory of liver cancer and for physicians to support them in their journey.

Hepatology Associates Course, Part 1: Hepatology Associates as Leaders in Multidisciplinary Care

Convention Center: Room 146C, Level 1

The Associates Course expands the knowledge base of participants to improve patient outcomes in behavioral, nutritional, and pharmacologic interventions in chronic liver disease. Speakers explore topics including: (1) novel treatment models of chronic hepatitis C and MASLD/MASH; (2) pharmacist driven management of chronic liver disease; (3) resource-limited management of chronic liver disease; and (4) palliative approaches to management of patients with chronic liver disease.



SUNDAY, NOVEMBER 9

8 – 9:30 AM

The American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy: Gastroenterology Update for the Hepatologist

Convention Center: Ballroom C, Level 3

Planned in partnership with the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy, this update provides the hepatology specialist with guidance on the management of common gastrointestinal challenges when caring for patients with decompensated cirrhosis. Presenters review the latest evidence in the management of complex liver diseases including key challenges in endohepatology; management of large polyps; dual therapy in primary prophylaxis of variceal bleeding; and preoperative management of the patient with MASLD-induced cirrhosis.

The Right Test at the Right Time: Sorting out the Myriads of New Liver Tests

Location: Convention Center: Ballroom B, Level 3

The myriad of imaging and allied tests available to evaluate known or suspected liver disease and liver cancers can be bewildering. In this session several of these techniques, including MRI, ultrasound, elastography and prognostic scores are considered.

8 – 10:30 AM

Global Consensus Endpoints for Clinical Trials: MetALD (Joint with EASL), ALD, MASLD, and Alpha-1 Antitrypsin Deficiency

Convention Center: Ballroom A, Level 3

As the landscape of liver disease evolves, so too must our tools for evaluating therapeutic efficacy and disease progression. This cutting-edge session will explore the latest advances and ongoing debates surrounding clinical trial and real-world endpoints for metabolic dysfunction-associated alcohol-related liver disease (MetALD), alcohol-associated liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), and alpha-1 antitrypsin deficiency (AATD). For MetALD, we will present the consensus endpoints developed by the AASLD/EASL MetALD Working Groups. Experts will address the challenges of defining meaningful and harmonized endpoints across overlapping phenotypes, the role of biomarkers and imaging, and regulatory considerations in early- and late-phase trials. Emphasis will be placed on how to tailor endpoints to the unique pathophysiology of each disease while also considering patient-centered outcomes and emerging surrogate markers. This session is essential for clinicians, researchers, and industry stakeholders involved in trial design and drug development for liver diseases.

8 – 8:30 AM

Thomas E. Starzl Transplant Surgery State of the Art: Advances in Artificial Intelligence and Technology in Liver Transplantation

Convention Center: Hall A, General Session, Concourse Level

8:30 – 9:30 AM

Liver Transplant Plenary

Convention Center: Hall A, General Session, Concourse Level

9:45 – 10:15 AM

Abstract Highlights Station: Hepatitis C

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

Liver Fellow Network Podcast

Convention Center: Science in the Park, Site B, Level 3

9:45 – 10:45 AM

AASLD/TASL – Delta Hepatitis: What is New?

Convention Center: Room 143, Level 1

The hepatitis D virus is a defective small RNA virus that causes acute hepatitis, acute liver failure, and chronic hepatitis, often leading to rapid progression to cirrhosis and its complications. In this Community Conservation, we will review recent updates on the epidemiological data of HDV, the clinical course of HDV-related liver disease, and the challenges associated with HDV treatment.

Clinical Trials Expo

Convention Center: The Park @ TLM, Meet-Up #4-6, Level 2

Join members of the Liver Leaders Council (LLC) in the Patient Lounge for a meet and greet to learn more about Clinical Trials.

AASLD/ALEH Meet-Up

Convention Center: TLM @ The Park, Meet-Up Space #1

Join our Latin American leadership and members for a casual meet-up at The Park @ TLM — a new networking opportunity designed for connection and conversation. Come enjoy an hour of socializing, light snacks, and great company!

NIH Corner – CDC DVH

Convention Center: Room 146A, Level 1

CDC's Division of Viral Hepatitis Director Carolyn Wester will discuss the on-going work at DVH and the division's role in the White House Hepatitis C Elimination plan.

SUNDAY, NOVEMBER 9

9:45 – 10:45 AM

Pathologists Are from Mars, Hepatologists Are from Venus: Decoding Steatotic Liver Disease

Convention Center: Room 201, Level 2

The clinical significance of findings in liver biopsies exhibiting steatotic liver disease (MASLD, MetALD, MASH) are the focus of this session. Presentations and discussion examine some of the interpretive issues that pertain to the new steatotic liver disease category MetALD, i.e., whether it is feasible to distinguish contribution or features of alcohol-related findings from MASLD only or MASH only. Metabolic diseases (e.g., Wilson disease or alpha-1 antitrypsin deficiency) and DILI with a steatohepatic pattern (e.g., methotrexate) are discussed with an emphasis on distinguishing these entities from other categories of steatotic liver disease. In addition to pathology, the session highlights the importance of utilization of pathology reports to facilitate diagnosis and further work-up, and the utility and limitations of liver biopsy to narrow a differential diagnosis. Case presentations illustrate the importance of clinicopathologic correlation in different clinical settings.

Special Interest Groups (SIG) Business Meetings

o Liver Transplantation | Convention Center: Room 145, Level 1

Strategies for Publication Success

Convention Center: Room 206, Level 2

A panel of editors from *Hepatology*, *Hepatology Communications*, and *Liver Transplantation* offer expert advice on streamlining both prepublication and post publication processes. Panelists share valuable tips to help authors with their publications by effectively presenting their research to editors, reviewers, and readers. Topics include study design, manuscript preparation, addressing reviewer feedback, and utilizing search engines and social media for optimal post publication impact.

The Expanding Role of Advanced Practice Providers in Hepatology: A Collaborative Approach to Liver Care

Convention Center: Room 146C, Level 1

This community conversation brings together a diverse group of hepatology experts and advanced practice providers (APPs) to discuss the integral role APPs play in the multidisciplinary care of patients with liver disease. The discussion showcases how APPs contribute to improving patient outcomes, fostering innovative care models, and addressing challenges in the management of liver conditions.

VA Premium Meet-Up

Convention Center: The Park @ TLM, Meet-Up #3, Level 2

10 – 10:45 AM

Chronic Hepatitis B in Focus: Practical Strategies for Patient-Centered Care

Supported by: GSK Medical

Convention Center: Exhibit Hall DE, TLM Theater 1

This disease state education theater will focus on chronic hepatitis B, covering the standard of care, patient care cascade, and clinical management considerations. Expert insights will be shared through engaging case studies and a dynamic panel discussion.

Clinical Deep Dive: Unlocking the Treatment Potential of Rezdiffra

Supported by: Madrigal

Convention Center: Exhibit Hall DE, TLM Theater 2

Please join us for an engaging and highly anticipated educational panel presentation focusing on a treatment option for patients with MASH, including the clinical data and patient cases.

11 – 11:30 AM

Hyman J. Zimmerman Hepatotoxicity State of the Art: Systemic Therapy for Hepatocellular Carcinoma in 2025 – Where Are We Now?

Convention Center: Hall A, General Session, Concourse Level

Laura Kulik, MD will present the Hyman J. Zimmerman Hepatotoxicity State of the Art Lecture, "Systemic Therapy for Hepatocellular Carcinoma in 2025: Where Are We Now?"

11 AM – 12:30 PM

American Association for the Study of Liver Diseases and Asian Pacific Association for the Study of the Liver Joint Symposium: Acute-on-Chronic Liver Failure – Contrasting Perspectives from the East and West

Convention Center: Room 146B, Level 1

Acute-on-chronic liver failure (ACLF) is the focus of this joint symposium from AASLD and the Asian Pacific Association for the Study of the Liver (APASL). ACLF is a complex syndrome characterized by acute hepatic decompensation in the setting of chronic liver disease leading to multiorgan failure and high short-term mortality. However, the definition, classification, and management strategies for ACLF vary significantly between APASL and AASLD guidelines. The program begins with an in-depth exploration of ACLF definitions as per APASL and AASLD, highlighting key clinical differences via case-based presentations. Expert discussions follow focusing on management strategies from both AASLD and APASL perspectives. While AASLD emphasizes early liver transplantation and intensive care, APASL advocates for aggressive medical management, including liver regeneration therapies. Understanding these distinct approaches is crucial for optimizing patient care, particularly in resource-limited settings.



SUNDAY, NOVEMBER 9

11 AM – 12:30 PM

Basic Science Workshop, Ribonucleic Acid Nanomedicine: Reprogramming Cells to Transform Liver Outcomes, Part 2 – Transforming Chronic Liver Disease: Breakthroughs and Clinical Updates in Ribonucleic Acid Nanotherapeutics

Convention Center: Room 207, Level 2

RNA nanomedicine has emerged as a groundbreaking approach for safely delivering genetic instructions into target cells, enabling their reprogramming without degradation. Its significance was underscored during the COVID-19 pandemic with the successful deployment of mRNA-based vaccines formulated using lipid nanoparticles. These nanoparticles, available in various formulations, act as carriers to transport RNA directly into target cells for therapeutic action. Patisiran and lumasiran – 2 FDA-approved RNA interference (RNAi) agents delivered via lipid nanoparticles (RNA nanotherapeutics) – exemplify this new generation of targeted therapies. These treatments have significantly reduced the need for liver transplantation in patients with genetic conditions such as amyloidosis and hyperoxaluria. Consequently, referrals for liver transplantation due to these metabolic disorders have dramatically declined, highlighting the transformative potential of RNA nanomedicine in clinical practice. In this workshop, experts review the transformative world of RNA nanomedicine; explore its role in delivering genetic instructions with unparalleled precision; discover how advancements in lipid nanoparticle (LNP) formulations are enabling breakthrough therapies; and gain insights into the latest clinical applications that are reshaping treatment paradigms, such as reducing the need for liver transplantation in genetic and metabolic disorders.

Elements of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis for Pediatric and Adult Patients

Convention Center: Room 209, Level 2

Developed by the Patient Advisory Group, this session explores MASLD and MASH from adolescence to adulthood, including approaches to improve treatment outcomes and strategies for early adoption of exercise and nutrition plans.

From Mice to Medicine: Decoding Alcohol Associated Liver Disease Pathways and Therapies

Convention Center: Ballroom B, Level 3

This meeting session focuses on advancing our understanding of alcohol-associated liver disease (ALD) through cutting-edge research utilizing both mouse and human models. The session highlights key mechanisms and mediators of ALD, including oxidative stress, inflammation, and the gut-liver axis. It also explores the interplay between the liver and adipose tissue, the impact of environmental factors, and the potential of GLP1 as a therapeutic target. The objective is to foster discussion and collaboration around these diverse yet interconnected pathways to inform future research and treatment strategies.

Hepatology Associates Course, Part 2: Novel Insights from Hepatology Associates

Convention Center: Room 146C, Level 1

The Associates Course expands the knowledge base of participants to improve patient outcomes in behavioral, nutritional, and pharmacologic interventions in chronic liver disease. Speakers explore topics including: (1) novel treatment models of chronic hepatitis C and MASLD/MASH; (2) pharmacist driven management of chronic liver disease; (3) resource-limited management of chronic liver disease; and (4) palliative approaches to management of patients with chronic liver disease.

Innovative Translational Studies in Cholestatic Disorders

Convention Center: Room 202, Level 2

Deeper investigations into the pathogenesis of AIH, PBC and PSC requires application of novel tools. This session highlights new discoveries in human and pre-clinical models of autoimmune and cholestatic disorders by the application of modern sophisticated analyses.

MASH: Promising Aspects from the Bench

Convention Center: Ballroom A, Level 3

Navigating the Complexities of Liver Transplantation in Challenging Candidates: Obesity, Advanced Age, Complex Anatomy, and Frailty

Convention Center: Room 145, Level 1

This clinical symposium focuses on unique medical and surgical aspects of selection and management of liver transplant candidates with advanced age, obesity, and/or frailty. Topics include: medical and endoscopic management of obesity before transplantation; the role of prehab for frail transplant candidates; selection of transplant candidates with advanced age; and surgical anatomical challenges in liver transplantation.

Promoting Equity and Access to MASLD Care

Convention Center: Room 146A, Level 1

This session covers epidemiologic trends and social determinants of health that affect access to MASLD care.

Small Molecules, Big Consequences: Mechanisms of Hepatotoxicity

Convention Center: Ballroom C, Level 3

This session highlights novel basic science research investigating mechanisms of hepatotoxicity. This session spans liver injury and repair for a variety of disease models including acetaminophen-induced liver injury, ethanol hepatotoxicity, induction of tumorigenesis and HCC, and the role of coagulation in severe acute liver injury.

SUNDAY, NOVEMBER 9

11 AM – 12:30 PM

The Liver Fellow Network Presents Hepatology Plus: Combining Hepatology Training With Other Training Pathways

Convention Center: Salon GH, Level 1

This program from the Liver Fellows Network highlights dual training opportunities with hepatology. Significant overlap exists between hepatology and other specialties such as hepatology-addiction medicine, hepatology-obesity medicine, hepatology-critical care medicine, hepatology-palliative care medicine, and hepatology-advanced endoscopy. Presenters share their personal experiences with dual training focusing on their training journey, current dual training opportunities in their specialty, and integration of the dual training into clinical practice

12:30 – 1 PM

Comprehensive CHB Testing: Quantitative & Qualitative HBsAg and Beyond

Supported by: GSK

Convention Center: Exhibit Hall DE, TLM Theater 1

This session will explore the clinical significance of comprehensive biomarker testing in chronic hepatitis B (CHB), focusing on how quantitative and qualitative HBsAg, HBeAg, and HBV DNA testing can help offer more personalized care to CHB patients by characterizing disease phases, supporting better-informed treatment decisions, and improving monitoring strategies.

Summary of TERLIVAZ® (terlipressin): The First FDA-approved Treatment for HRS in Adults with Rapid Reduction in Kidney Function

Supported by: Mallinckrodt Pharmaceuticals

Convention Center: Exhibit Hall DE, TLM Theater 2

The Summary of TERLIVAZ® (terlipressin): the first FDA-approved treatment for HRS in adults with rapid reduction in kidney function. This TLM theater will highlight the importance of early recognition and current diagnosis and treatment recommendations for hepatorenal syndrome-acute kidney injury (HRS-AKI).

12:30 – 2 PM

Advancing the Management of Cholestatic Liver Disease: Optimizing Treatment Pathways and Emerging Therapies

Supported by: Ipsen Biopharmaceuticals, Inc.

Organized by: PeerVoice, and CME provider: USF Health

Convention Center: Room 152, Level 1

In this activity, experts in adult and paediatric hepatology and gastroenterology explore practical strategies and evidence-based tools to diagnose and facilitate tailored treatment decision-making for primary biliary cholangitis (PBC) and progressive familial intrahepatic cholestasis (PFIC).

New Horizons in MASH Management

Supported by: Inventiva

Organized by: Medscape Education

Convention Center: Room 150, Level 1

Join us for a symposium on metabolic dysfunction-associated steatohepatitis (MASH) designed to encourage the exchange of ideas between leaders in the field and attendees.

AASLD Past Presidents' Luncheon

Convention Center: Room 206, Level 2

12:45 – 1:15 PM

Abstract Highlights Station: Public Health Public Health/Health Care Delivery (PHHD) SIG

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

The Power of Multidisciplinary Care for ALD

Convention Center: Science in the Park, Site B, Level 3

Come discuss the importance of multidisciplinary care for patients with alcohol-associated liver disease with Dr. Hanna Blaney and Dr. Jay Luther, two recent Hepatology Communications authors.

12:45 – 1:30 PM

MTE #22 Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease

Convention Center: Room 140A, Level 1

Experts provide insights into the treatment of alcohol use disorder (AUD) in patients with alcohol-associated liver disease, with a focus on cirrhosis. Topics include the efficacy of FDA-approved therapeutics and off-label use of medications for AUD, and how to manage side effects of these agents.

MTE #23 The "GENIE" in the Hepatitis B Bottle: What's New in Genetic Modulation for Hepatitis B Cure?

Convention Center: Room 140B, Level 1

Discover the latest advances towards a functional cure of HBV infection. Experts present information about the latest clinical and basic studies exploring gene editing therapy, epigenetic modulation such as gene silencing using CRISPR/Cas9, and viral genetic targets such as antisense oligonucleotide (ASO) and small interfering RNA (siRNA). Experts and participants discuss these topics in the context of the prospect of a hepatitis B cure.



SUNDAY, NOVEMBER 9

12:45 – 1:30 PM

MTE #24 To Bleed or Not to Bleed: The Role of Coagulation in Liver Disease

Convention Center: Room 144C, Level 1

Experts discuss the role of the coagulation cascade and the importance of the intricate balance between thrombosis and hemostasis in normal liver homeostasis and in liver diseases such as DILI, MASH, and MASLD.

MTE #25 Advancement in Noninvasive Tests for the Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis

Convention Center:

Presenters explore the latest developments in noninvasive tests (NITs) for diagnosing metabolic dysfunction-associated steatohepatitis (MASH). The session covers the principles, applications, and clinical integration of advanced NITs such as imaging techniques, biomarkers, and emerging tools. Experts focus on how these methods enhance diagnostic accuracy, reduce reliance on invasive liver biopsies, and improve patient care.

MTE #26 Reproductive Health of Liver Transplant Recipients

Convention Center: Room 154, Level 1

Experts provide an overview of reproductive health issues and pregnancy in liver transplant recipients, including the natural history of posttransplant fertility, recommended changes in immunosuppressive pharmacotherapy during pregnancy, and fetal outcomes.

MTE #27 Management of Clinically Significant Hypersplenism

Convention Center: Room 158, Level 1

In this interactive session, experts focus on the diagnosis of clinically significant hypersplenism, related clinical complications, and management approaches including emerging interventional approaches to clinically important hypersplenism.

1 – 1:45 PM

Special Interest Groups (SIG) Business Meetings

- o **Hepatology Associates** | Convention Center: Room 146C, Level 1
- o **Pediatric Liver Disease** | Convention Center: Room 202, Level 2

1–2 PM

Sunday Poster Presenters Hall Hour

Convention Center: Hall DE (Posters & Exhibits), Level 2

The following poster categories will be in the Poster Hall:

- o Health Services and Public Health Research
- o Hepatobiliary Neoplasia
- o Liver Fibrogenesis and Non-Parenchymal Cell Biology
- o Liver Transplantation and Liver Surgery
- o Metabolic and Genetic Disease

1:30 – 2 PM

Could Your Patients with Unexplained Cholestasis Have Progressive Familial Intrahepatic Cholestasis (PFIC)? When to Suspect and Considerations for Treatment

Supported by: *Mirum Pharmaceuticals*

Convention Center: Exhibit Hall DE, TLM Theater 1

Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders associated with the accumulation of toxic bile acids and progressive liver injury. In this presentation, Dr Gish will review the signs / symptoms of PFIC, examine the role of genetic testing in diagnosis, and discuss considerations for treatment of adults with PFIC.

Zetomipzomib and the PORTOLA Trial: A Transformative Step Forward in Autoimmune Hepatitis (AIH)

Supported by: *Kezar Life Sciences, Inc.*

Convention Center: Exhibit Hall DE, TLM Theater 2

This session will present findings from the Phase 2a PORTOLA trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in autoimmune hepatitis. Attendees will hear insights on the study design and clinical outcomes, followed by expert discussion on the potential role of immunoproteasome inhibition in advancing treatment for this challenging disease.

2 – 6 PM

Point-of-Care Liver Ultrasonography Course: Basic Skills, Part 1

Marriott Marquis: Marriott Marquis Ballroom, Salons 1–5

This symposium introduces the concept of point-of-care ultrasonography (POCUS) of the liver as an extension of the clinical exam to be performed by hepatology clinicians. Presenters provide a rationale for the use of POCUS, the basics of liver ultrasonography, common applications, and a path to implement POCUS in clinical practice.

2 – 3:30 PM

Academic Advancement, Promotion, and Tenure for Under-Represented Groups in Hepatology

Convention Center: Room 146A, Level 1

Cosponsored by the Inclusion and Diversity Committee, the Women's Initiatives Committee, and the LGBTQ Taskforce, the program centers on academic advancement, promotion, and tenure for under-represented groups in hepatology. Under-represented groups—which can vary by context and geography — may identify by race, ethnicity, gender identity or sexual orientation, disability, etc. Speakers' presentations focus on various aspects of academic advancement, including talks aimed at junior faculty and trainees regarding academic advancement and promotion for clinical track faculty, and academic advancement and tenure for research and basic science-oriented faculty. Barriers to academic rank promotion for nurse practitioner and physician associate faculty are discussed as well as the need for a consistent framework for academic advancement for across institutions. All are welcome!

2 – 3:30 PM

SUNDAY, NOVEMBER 9

Beyond the Liver: Addressing Mental Health Challenges for Hepatologists and Practitioners

Convention Center: Ballroom C, Level 3

Cosponsored by the Training and Workforce Committee, the Women's Initiative Committee, and the Liver Fellow Network, this session is dedicated to highlighting the mental health and wellness of physicians and practitioners in hepatology and liver transplant practice. Special attention is focused on: (1) the risk of physician suicide; (2) normalization of seeking professional help for mental health challenges; (3) how seeking professional mental health help aligns with maintenance of professional licensure and ongoing practice; and (4) institutional opportunities to improve support, and paths forward. Speakers offer unique perspectives on these topics from personal, institutional, and national levels. The session tackles the challenges health care practitioners face and risk factors for poor mental health and physician burnout, and offers strategies for resiliency, empowerment, and advocacy.

NOTE: This session will not be livestreamed, and recording will be limited. Attendee questions will be edited out of recordings so that questioners feel able to contribute their queries as they feel comfortable. The session will also utilize Slido for anonymous audience interactions and input about their experiences with mental health.

Bridging Hepatology and Transplant: Key Insights for Nontransplant Clinicians on Indications, Evaluation, and Donor Strategies

Convention Center: Room 146C, Level 1

Description: This comprehensive session provides an in-depth review of critical topics surrounding liver transplantation. Presenters guide attendees through the latest updates on liver transplant indications, the evaluation process, allocation systems, and different donor types including living, deceased, and expanded criteria donors. Through case studies and expert-led discussions, participants gain a robust understanding of how to navigate the complexities of liver transplant care and improve patient outcomes.

Cholestatic Liver Diseases: New Treatments, Tools, and Symptom Management

Convention Center: Room 209, Level 2

Developed by the Patient Advisory Group, specialists in the cholestatic liver diseases primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) collaborate with patient advocates to shine a light on: (1) newly available treatments for PBC; (2) a new tool for patients to use during their first visit with their hepatologist; (3) an exciting registry for patients with PSC; and (4) what patients need to know about symptom management.

Donor and Allocation Considerations in Liver Transplantation

Convention Center: Room 145, Level 1

Diseases: Hepatocellular Carcinoma Risk, Surveillance, and Diagnosis

Convention Center: Room 146B, Level 1

HCC and other liver nodules can develop in patients with Fontan-associated liver disease (FALD) and other vascular liver diseases, which may include conditions such as heart failure and Budd-Chiari syndrome. Currently, the Liver Imaging Reporting and Data System (LI-RADS) – a widely used tool for the imaging diagnosis of HCC – cannot be applied to these patients due to insufficient data and the low specificity of imaging in this context. This session provides an overview of cardiac/vascular liver disease and associated HCC risk. Speakers discuss the controversial topic of HCC surveillance in patients without cirrhosis, explore appropriate surveillance strategies for high-risk patients including those with cirrhosis, and address the diagnostic challenges faced by this population.

General Update: Latest Advances in Hepatology

Convention Center: Ballroom B, Level 3

Presenters offer a comprehensive exploration of 3 key areas in hepatology: MASH, alcohol-associated liver disease, and primary biliary cholangitis (PBC). Attendees learn how to optimize patient selection for MASH therapies by utilizing clinical and diagnostic criteria, distinguishing MASH from cirrhosis, and incorporating fibrosis assessment to guide treatment strategies. Speakers also address the complexities of managing alcohol-associated liver disease, focusing on early recognition, evidence-based interventions, and overcoming long-term care challenges. Finally, participants gain insights into the diagnosis and treatment of PBC, including the use of current therapies and effective monitoring strategies to enhance patient outcomes.

MASH Clinical Trials

Convention Center: Hall A – General Session, Concourse Level

Metabolic Modifiers and Surveillance Strategies in HBV: Epidemiologic Insights and Global Elimination Goals

Convention Center: Ballroom A, Level 3

This session will examine the intersection of chronic hepatitis B with metabolic risk factors, pharmacologic exposures, and evolving biomarkers in liver disease progression and surveillance. Topics will include the protective association of statins with HCC risk, the impact of hepatitis B on fibrosis in MASLD and impact of GLP-1 on outcomes in HBV. Additional talks will address the potential for HBsAg quantification to define thresholds for discontinuing HCC surveillance and global progress toward HBV elimination targets.

Fontan-Associated and Other Vascular Liver



SUNDAY, NOVEMBER 9

2 – 3:30 PM

Hepatotoxicity and Pediatric Liver Disorders Special Interest Groups Joint Symposium, Part 1. Drug-Induced Liver Injury: Drug-Induced Liver Injury Across the Lifespan – Advances in Management

Convention Center: Room 202, Level 2

Topic experts discuss the risk of DILI and phenotypes of presentation from children to the elderly. Presenters review emerging and novel therapies associated with DILI, provide an update on blood-based biomarkers of DILI, and highlight research priorities to address knowledge gaps in this constantly evolving space.

The Editors Cut: Translational Studies

Convention Center: Room 207, Level 2

Associate Editors from the journal HEPATOLOGY lead a critical discussion of the most notable and influential translational research papers published in the past year. HEPATOLOGY Associate Editors appraise the most cutting-edge, game-changing scientific advances. A panel discussion with the speakers, Editor-in-Chief Gregory Gores, and Deputy Editor Harmeet Malhi highlights the impact of selected papers on translational advances in the field.

3:30 – 4:15 PM

Advances in MASH: Data from a Phase 3 Study

Supported by: Novo Nordisk, Inc.

Convention Center: Exhibit Hall DE, TLM Theater 2

Join us as we discuss the importance of early identification of MASH (metabolic dysfunction-associated steatohepatitis), including how to accurately identify and select patients who are at risk for clinically significant fibrosis. We will also discuss clinical trial data for patients with MASH and stage 2 or 3 fibrosis.

Evolving Approach to Second-line Treatment in PBC: A Case-based Discussion

Supported by: Ipsen

Convention Center: Exhibit Hall DE, TLM Theater 1

This session will highlight evolving approaches to second-line treatment in Primary Biliary Cholangitis (PBC) through a case-based discussion. It will provide practical insights and foster a dynamic exchange between leading hepatologists.

3:45 – 4:15 PM

Abstract Highlights Station: Hepatitis B Delta (HBV/HDV) SIG

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

3:45 – 4:15 PM

ILTS Portopulmonary Hypertension Guideline Update

Convention Center: Science in the Park, Site B, Level 3

Come discuss the recent International Liver Transplantation Society guideline update on portopulmonary hypertension with one of the authors behind the guideline.

3:45 – 4:45 PM

Advancing Liver Care Through Innovative Associate & APP-Led Strategies

Convention Center: Room 146C, Level 1

This session highlights the vital contributions of associates and advanced practice providers (APPs) in advancing hepatology care through real-world insights, innovative treatment strategies, and impactful quality improvement initiatives. Through data-driven research and patient-centered approaches, these presenters demonstrate the power of associate- and APP-led initiatives to improve outcomes and expand access in diverse clinical settings.

Elevating Liver Disease Globally: How Do We Get There?

Convention Center: Salon GH, Level 1

This is a Healthy Liver, Healthy Lives (HLHL) symposium bringing the global community together to elevate liver disease as a global health priority.

NIH Corner – NCI

Convention Center: Room 146B, Level 1

National Cancer Institute program staff will discuss current funding opportunities for basic and clinical research at the National Cancer Institute and take questions regarding the grant process and funding opportunities.

Patient Engagement in Pediatric Liver Disease: Experiences From the A-LiNK, PFIC.org, and Starzl Networks

Convention Center: Room 201, Level 2

This session updates the community on the experience and expertise of patient engagement from 3 ongoing collaboratives:

- The Autoimmune Liver Disease Network for Kids (A-LiNK) and the A-LiNK connections
- PFIC.org and their Patient-Centered Outcomes Research Institute (PCORI) funded IMPACT project (identifying research targets by merging patient and clinician treatment information)
- the Starzl Network for Excellence in Pediatric Transplantation and their PCORI funded PARTNER AD³vance project (patient-centered research in pediatric transplant – engaging families and recipients – adolescent and young adult advisors)

Presenters highlight the importance of patient engagement in setting research agendas, strategies for successful patient engagement, and how patient engagement affects project development and progress.

SUNDAY, NOVEMBER 9

3:45 – 4:45 PM

Program Directors Workshop

Convention Center: Room 143, Level 1

This workshop addresses the current state of advanced hepatology training. Speakers discuss salient topics around transplant hepatology training and workforce considerations, including recruitment and participation, retention, funding, and upcoming changes to the American Board of Internal Medicine blueprints.

Special Interest Groups (SIG) Business Meetings

- o Hepatotoxicity | Convention Center: Room 202, Level 2

Meet-Up #2

Convention Center: The Park @ TLM, Meet-Up #1-6, Level 2

- o Meet-Up 1: MASLD
- o Meet-Up 2: CALD
- o Meet-Up 3: Clinical Practice
- o Meet-Up 4: HCV
- o Meet-Up 5: PHHD
- o Meet-Up 6: Early Career Meet-Up, hosted by The Liver Fellow Network

Open to students and trainees who are early career professionals, the Early Career Meet-Up is a networking event for those in hepatology to connect, collaborate, and make an impact.

Taking Hepatology Associates to the Next Level

Convention Center: Room 206, Level 2

This community conversation is designed to inspire and guide hepatology associates as they transition from competency to expert practice. Through a dynamic panel discussion, participants explore strategies to elevate their careers by engaging with professional organizations, expanding clinical and leadership skills, and mastering the art of self-advocacy. Panelists share insights on leveraging current skill sets, fostering peer collaboration and mentorship, and creating pathways for career growth in hepatology.

4 – 5:30 PM

My Personal Experience with Palliative Care

Convention Center: Room 209, Level 2

Developed by the Patient Advisory Group, this session focuses on types of palliative care throughout various stages of liver disease, and how palliative care can be helpful for both patients with liver disease and their caregivers.

5 – 6:30 PM

Advancing Care for Critically Ill Patients with Liver Disease: Acute-on-Chronic Liver Failure and Beyond

Convention Center: Ballroom B, Level 3

Members of the Acute-on-Chronic Liver Failure Special Interest Group present strategies to advance and optimize the care of critically ill patients with advanced liver disease and acute-on-chronic liver failure. Topics include the role of liver transplantation, optimization of renal function, and management of hemodynamics and sepsis. The session concludes with a panel discussion.

American Association for the Study of Liver Diseases and Japan Society of Hepatology Joint Symposium: Emerging Strategies for Alcohol-Associated Liver Disease Care

Convention Center: Room 146B, Level 1

This joint symposium from the Japan Society of Hepatology and AASLD addresses the important topic of alcohol-associated liver disease (ALD) care from an international perspective. Topics focus on ALD in Japan and in the United States. The first half of the session explores challenges and opportunities in the diagnosis and management of ALD. The second half discusses surgical and medical strategies for the management of alcohol-associated hepatitis. The session concludes with a discussion of future collaborative research opportunities and a question-and-answer period.

American Association for the Study of Liver Diseases Guidelines: What's New in 2025

Convention Center: Hall A, General Session, Concourse Level

Prepared by the Practice Guidelines Committee, this session highlights newly published AASLD guidelines addressing critical issues regarding treatment of viral hepatitis B. Speakers also present an extensive list of topics pertaining to liver transplantation in adults ranging from pretransplant evaluation to management of various graft-related and non-graft-related postoperative complications.

Cellular Catalysts of Fibrosis: Stromal Signals, Exosomes, and Inflammation in the Diseased Liver

C Convention Center: Room 146C, Level 1

This session highlights emerging mechanisms by which non-parenchymal cells (NPCs), particularly hepatic stellate cells (HSCs), orchestrate liver fibrogenesis in the context of metabolic dysfunction and chronic injury. Presentations will examine the impact of exosomal microRNAs, inflammasome activation, mitochondrial stress, and Notch/YAP signaling on HSC activation and fibrotic progression. Together, these studies illuminate how cell-cell communication, immune-metabolic crosstalk, and novel therapeutic targets shape liver fibrosis and hepatocellular carcinoma risk.



SUNDAY, NOVEMBER 9

5 – 6:30 PM

Hepatotoxicity and Pediatric Liver Disorders Special Interest Groups Joint Symposium, Part 2. Drug-Induced Liver Injury: Emerging Trends in Drug-Induced Liver Injury – From Children to Adults

Convention Center: Room 202, Level 2

Topic experts discuss the risk of DILI and phenotypes of presentation from children to the elderly. Presenters review emerging and novel therapies associated with DILI, provide an update on blood-based biomarkers of DILI, and highlight research priorities to address knowledge gaps in this constantly evolving space.

Immunobiology, Immunosuppression, and Complications in Liver Transplantation

Convention Center: Room 145, Level 1

Inclusion and Diversity Committee Symposium: Innovative Approaches to Address Sociocultural Complexities in Hepatology and Transplant Care

Convention Center: Room 146A, Level 1

Join the AASLD Inclusion and Diversity Committee in exploring the role of social determinants of health, and cultural and language differences in hepatology and liver transplant care. Presenters provide actionable solutions to address these care complexities to optimize health outcomes in patients with liver disease. Additionally, speakers highlight various ways in which community-based research can be conducted to explore these areas of health care in greater detail.

MASH Therapies: Approved Drug or Real-World Data

Convention Center: Ballroom A, Level 3

Next-generation HBV Therapeutics: Emerging Therapies and Search for Functional Cure

Convention Center: Room 207, Level 2

This session will feature translational and early-phase clinical studies that are advancing the therapeutic landscape for chronic hepatitis B. Highlights include a novel capsid assembly modulator, early stage HBV immune modulation trial, therapeutic vaccines antisense oligonucleotides in combination with pegylated interferon and a preclinical study of an epigenetic editing agent demonstrating HBV surface antigen loss through targeted DNA methylation. Together, these studies showcase innovative pathways toward viral suppression and functional cure.

5 – 6 PM

AASLD Trivia Night: Inaugural Edition

Convention Center: Ballroom C, Level 3

Join a team with your table and get ready to answer hepatology-related trivia questions. And — there will be prizes!

5:45 – 6:45 PM

Hepatology Associates Reception

Sponsored by: Mirum Pharmaceuticals

Convention Center: Member Lounge, Salon B

This exclusive event for hepatology associates offers a unique networking opportunity to share stories, insights, and build meaningful connections.

7 – 8 PM



Fellows' Reception

Offsite: The National Building Museum

Celebrate your achievements and connect with peers at the Fellows Reception, a special event dedicated to our Fellows and Associate Fellows of the American Association for the Study of Liver Diseases. This reception offers a special opportunity to network with fellow leaders and build lasting professional relationships within the hepatology community.

7:30 – 11:30 PM



Members' Reception

Sponsored by: Madrigal Pharmaceuticals and
Mirum Pharmaceuticals

Offsite: The National Building Museum

Join us at the Members Reception, an exclusive members-only event designed to celebrate and appreciate our dedicated AASLD members. This evening gathering provides an excellent opportunity to reconnect with fellow members, share your experiences, and engage with AASLD leadership.

MONDAY, NOVEMBER 10

7 – 7:45 AM

Meet-the-Expert (MTE) #29 Novel Diagnostics and Therapeutics for Wilson Disease

Convention Center: Room 140A, Level 1

Wilson copper storage disease (WD) research is rapidly evolving. New diagnostic and therapeutic approaches will alter the way the disease is managed in the years ahead. These scientific advances will ensure that patients are receiving accurate diagnoses and effective therapies, thus preventing end-organ injury. Experts review the current guidelines for the diagnosis and treatment of WD and contrast this with emerging novel diagnostics and therapeutics, including gene therapy.

MTE #30 Viral Reactivation After Immunosuppressive Therapy

Convention Center: Room 140B, Level 1

Experts provide an update on HBV, HCV, and HEV infections in immunocompromised patients, focusing on viral reactivation after immunosuppressive treatment. Topics include various types reactivation of viral hepatitis; at-risk patient populations; diagnostic criteria for reactivation of HBV, HCV, and HEV infection; preventive measures; effects of specific immunosuppressive therapies; and timing of antiviral treatment.

MTE #31 Navigating Bias in the Workplace: Practical Skills for Building a Culture of Allyship, Empathy, and Professionalism in Hepatology

Convention Center: Room 144C, Level 1

This joint Inclusion and Diversity Committee and LGBTQ+ Task Force session focuses on equipping participants with practical strategies to respond effectively to microaggressions and discrimination in professional settings, with an emphasis on fostering professionalism and allyship. Key topics include recognizing and addressing implicit biases, navigating tough conversations with colleagues, and responding to bias in ways that align with personal and professional values. Participants engage in interactive discussions, share experiences, and learn from real-world examples of encountering and addressing bias related to race, ethnicity, gender, sexual orientation, and more. Through guided exercises, attendees practice formulating responses that balance empathy, professionalism, and advocacy, ensuring they are prepared to respond thoughtfully in challenging moments. This session provides a platform for collaborative learning, encouraging participants to reflect on their own biases while gaining insights from the experiences of others.

MTE #32 Expanding the Donor Pool: Use of Hepatitis B Surface Antigen Positive Donors in Hepatitis B Seronegative Recipients

Convention Center: Room 149, Level 1

Experts present information addressing the safety and efficacy of transplantation of HBsAg-positive donor organs into hepatitis B seronegative recipients and long-term management of hepatitis B post transplantation in this patient population. Topics include patient and graft survival, and posttransplant management including the role of hepatitis B immunoglobulin, long-term HBV suppressive management, and HCC risk and surveillance.

MTE #33 Lifestyle Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: Nutrition and Exercise Prescription

Convention Center: Room 154, Level 1

Experts review the evidence behind the key recommendations for dietary and exercise habits with beneficial impact on MASLD and MASH. Participants learn about the best nutritional choices for metabolic comorbidities and prevention of cirrhosis complications. Presentations discuss an ideal exercise prescription and recommendations on how to maintain consistency of lifestyle changes.

MTE #34 Updates in Sinusoidal Obstruction Syndrome and Veno-Occlusive Disease

Convention Center: Room 158, Level 1

Join this interactive session that focuses on the diagnosis and management of sinusoidal obstruction syndrome and veno-occlusive disease. Topics include current diagnostic approaches for sinusoidal obstruction syndrome/veno-occlusive disease, available therapies, natural history of the condition, and patient prognosis.

7:45 – 8:15 AM

Abstract Highlights Station: Liver Cell Biology SIG

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

8 – 9:30 AM

Advances in Hepatitis Management

Convention Center: Room 207, Level 2

This session will highlight recent data on therapy for chronic hepatitis D, including real-world effectiveness, safety, and predictors of treatment response. Presentations will explore outcomes across various patient populations.



MONDAY, NOVEMBER 10

8 – 9:30 AM

American Association for the Study of Liver Diseases and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (AASLD/NASPGHAN) Course, Part 1 – Getting to the Heart of the Matter: Navigating Fontan-Associated Liver Disease

Convention Center: Room 146 C, Level 1

Hepatology, cardiology, and transplant medicine experts discuss the pathophysiology, clinical management, and long-term outcomes of Fontan-associated liver disease. The symposium highlights emerging research, diagnostic advancements, and multidisciplinary approaches to improve surveillance, treatment, and transplant decision-making for this unique patient population. Audience members learn from persuasive arguments by transplant surgeons regarding the options of isolated heart transplant versus combined heart-liver transplant for pediatric patients with Fontan failure. Attendees participate in this discussion by questioning presenters and voting how they would handle a challenging clinical case in light of the information presented.

Beyond the Bottle: Metabolic Drivers of Alcohol-Associated Liver Disease

Convention Center: Ballroom B, Level 3

This meeting session explores the complex relationship between metabolic dysfunction and alcohol-associated liver disease (ALD), with a focus on emerging clinical insights and risk stratification strategies. The included research abstracts examine the natural history and progression of ALD in the context of metabolic comorbidities, particularly following bariatric surgery. Key objectives include evaluating the risks and potential mitigators of ALD in post-surgical populations and assessing the effectiveness of population-based tools for early identification and risk stratification. The session aims to inform clinical decision-making and guide future research directions in the management of ALD.

Clinical Management of Portal Hypertensive Complications: Hepatic Encephalopathy and Renal Failure

Convention Center: Room 202, Level 2

This abstract session will present the latest research on complications of portal hypertension, including hepatic encephalopathy, ascites, and HRS-AKI. Authors will present novel findings and innovative approaches in diagnosing and managing these conditions, which are pivotal challenges in patients with advanced liver disease.

Emerging Determinants and Outcomes in Liver Disease: From Population Trends to Patient-Centered Insights

Convention Center: Room 145, Level 1

Insights into Hepatobiliary Neoplasia

Convention Center: Ballroom C, Level 3

Participants in this session will learn about novel techniques to understand hepatobiliary neoplasia, including the interaction of known carcinogenic stimuli and the immune system.

Intersection of Sexual, Reproductive, and Liver Health in a Diverse Population

Convention Center: Room 146B, Level 1

Sexual, reproductive, and cultural factors profoundly impact liver health, yet these dimensions are often overlooked in hepatology care. This program explores the intersection of sexual, reproductive, and liver health in a diverse population, including people with chronic liver disease, HIV, and those who identify as LGBTQ+. Presenters provide insight and suggestions to offer culturally sensitive hepatology care with the goal of empowering clinicians to deliver inclusive, patient-centered care, improving outcomes and equity in liver health across diverse populations. Presentation topics include: (1) oral contraceptive use and pregnancy counseling, including infertility treatment and in vitro fertilization in patients with chronic liver disease and post liver transplantation; (2) common reproductive and liver issues for LGBTQ+ patients, including the hepatologic effects of gender affirming hormone therapy, use of HIV pre-exposure prophylaxis in people with chronic liver diseases, and transplant access; (3) the increasing prevalence of MASLD in people living with HIV (PWH)—which also disproportionately affects the LGBTQ+ and other marginalized populations—exploring unique risk factors, pathophysiology, and management strategies; and (4) culturally sensitive approaches for liver health counseling and practical guidance for specialists and community practitioners to address obstacles faced by LGBTQ+, PWH, and other marginalized populations, especially under current climates.

MASH Diagnostics: Advances, Limitations, and the Path Ahead (Session 1)

Convention Center: Ballroom A, Level 3

Signals Across Systems: Microbiome, Immunity, and Neuroinflammation in Liver Disorders

Convention Center: Room 146A, Level 1

This session explores the complex, multisystem interactions that drive inflammation in liver disease, with a focus on gut-liver and liver-brain communication. Presentations highlight the roles of the microbiome in estrogen homeostasis, salivary and serum biomarkers in cirrhosis outcomes, and immune signaling pathways such as TLR8 and neutrophil recruitment in biliary and advanced liver disease. The session also delves into how hepatocyte-derived exosomes and β -catenin signaling impact microbiome balance, intestinal inflammation, and neuroinflammation, underscoring new therapeutic opportunities at the interface of immunity and inter-organ communication.

MONDAY, NOVEMBER 10

8 AM – Noon

Point-of-Care Liver Ultrasonography Course: Basic Skills, Part 2

Marriott Marquis: Marriott Marquis Ballroom, Salons 1-5

This symposium introduces the concept of point-of-care ultrasonography (POCUS) of the liver as an extension of the clinical exam to be performed by hepatology clinicians. Presenters provide a rationale for the use of POCUS, the basics of liver ultrasonography, common applications, and a path to implement POCUS in clinical practice.

8 – 8:30 AM

Leon Schiff State of the Art: Symptom Science in Hepatology and a Future of Improved Patient Outcomes

Convention Center: Hall A, General Session, Concourse Level

This lecture will explore the cutting-edge developments in symptom science within hepatology, emphasizing the critical role of understanding patient preferences in advancing care and improving outcomes. We will discuss the optimal and innovative tools for efficient determination of these preferences, enabling clinicians to tailor interventions to individual needs. We will highlight the methods and importance of patient-centered clinical trial design, ensuring that research is feasible and aligns with patient priorities.

8:30 – 9:30 AM

Clinical Plenary #2

Convention Center: Hall A, General Session, Concourse Level

9:45 – 10:15 AM

Abstract Highlights Station: Pediatric Liver Disorders (PLD) SIG

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

9:45 – 10:45 AM

AASLD/INASL: Global Perspectives on Hepatitis B Management in Pregnancy

Convention Center: Room 146B, Level 1

This interactive discussion explores the complexities of managing hepatitis B in pregnancy, highlighting the key differences in approaches between Asia and Western countries. Presentation topics include insights into region-specific guidelines; antiviral therapy options; neonatal immunoprophylaxis strategies; and the influence of cultural and health care system factors on care delivery. By comparing practices across regions, the session provides practical knowledge to optimize outcomes for pregnant women with hepatitis B and their newborns in diverse clinical settings.

Advancing Diversity, Equity, and Inclusion in Hepatology: New Challenges and Strategies for LGBTQ+ and Underrepresented Minority Communities

Convention Center: Salon GH, Level 1

Recognizing the ongoing challenges faced by LGBTQ+ individuals and underrepresented minorities (URMs) in health care, particularly amidst recent shifts in funding, policy, and societal attitudes, this community conversation session aims to address systemic barriers contributing to disparities in health care access and outcomes for these populations. The session highlights specific challenges, such as how changes in funding and policies may impact diversity, equity, and inclusion (DEI) initiatives in academic and health care settings. Strategies to sustain and enhance diverse workforce recruitment despite evolving regulations and restrictions are explored. Panelists also address new challenges facing LGBTQ+ patients and health care practitioners, including barriers to accessing equitable liver care and the broader implications of these obstacles on their health and well-being. By bringing together DEI leaders from academic institutions and frontline health care workers, this conversation seeks to identify practical solutions that ensure ongoing support for LGBTQ+ and URM individuals as both patients and health care practitioners. The ultimate goal is to foster a more inclusive hepatology community where diversity is not only acknowledged but celebrated, ensuring equitable health care delivery and professional opportunities for all.

American Association for the Study of Liver Diseases and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (AASLD/NASPGHAN) Course, Part 2 – Portal Hypertension: Learning from Data in Adults to Improve the Diagnosis and Management of Children

Convention Center: Room 146C, Level 1

Portal hypertension remains a challenging complication of pediatric liver disease with significant morbidity and mortality. Management of portal hypertension in adults and children can vary. This session reviews the diagnosis and management of pediatric portal hypertension, learning from adult data.

AASLD MASLD Practice Guidance Update: Semaglutide Therapy

Convention Center: Science in the Park, Site B, Level 3

Late Breaking! Join AASLD scientific leaders to discuss the latest AASLD MASLD Practice Guidance update. What has changed?!



MONDAY, NOVEMBER 10

9:45 – 10:45 AM

Assessing and Addressing Quality of Life and Patient-Reported Outcomes: Creating Shared Decision-Making for Hepatitis B Management and Treatment

Convention Center: Room 201, Level 2

Panelists highlight the perspectives of providers and people living with hepatitis B regarding strategies to assess and address patient-reported outcomes and cultivate shared decision-making that is informed by scientific evidence, provider expertise, and patient preferences. The diverse panel includes representatives of nonprofit organizations, health systems, academic institutions, and patient advocacy groups. A question-and-answer period follows speaker presentations.

Breaking News in MASH: FDA's Pathway for NIT-Driven Endpoints

Convention Center: Ballroom A, Level 3

This program is designed to explore the recent FDA announcement and *Hepatology* publication regarding the role of non-invasive tests (NITs) in MASH clinical trials. The session will review the regulatory perspectives, scientific evidence, and clinical implications of these developments. It will also provide a forum for open dialogue and audience engagement, highlighting both opportunities and challenges for integrating NITs into practice and research. Attendees will leave with a clearer understanding of how these updates may shape the future landscape of hepatology and drug development.

Emerging Livers Advance Practice Provider Meet-Up

Convention Center: The Park @ TLM, Meet-Up #1, Level 2

Emerging Livers Scholars

Convention Center: The Park @ TLM, Meet-Up #2, Level 2

NIH Corner – NIAAA

Convention Center: Room 146A, Level 1

National Institute of Alcohol Abuse and Alcoholism Director, Dr. George Koob, will present opening remarks on NIAAA's liver-related work, present on research opportunities, and answer audience questions.

Optimizing Transplant Access Through Outreach, Living Donation, and Machine Perfusion: New Practice Paradigms

Convention Center: Room 206, Level 2

Presenters explore new practice paradigms for optimizing liver transplant access and examine effective strategies for dissemination of knowledge regarding the benefit of living donor liver transplant (LDLT) through directed, nondirected, and paired donation. Other topics include the role of machine perfusion in improving transplant access, outreach hepatology and transplant clinics, telehepatology, and the role of minimally-invasive surgical techniques in the growth of LDLT programs.

Pediatric Liver Disorders (PLD) SIG

Convention Center: Science in the Park, Site A, Level 3

Rechallenge After Drug-Induced Liver Injury: A Debate of the Merits and Hazards from Industry, the US Food and Drug Administration, and Clinical Academia

Convention Center: Room 143, Level 1

Hepatologists are often asked if a patient can restart a medication after an episode of DILI. Utilizing a friendly debate format, presenters highlight key points about the risk/benefit analysis in rechallenge and how to identify patients suitable for a rechallenge trial. In addition, specific case scenarios with common medications are addressed. Given the nuances involved, the panel comprises stakeholders from academia, the pharmaceutical industry, and regulatory agencies to provide their perspective on the issue of rechallenge after DILI.

10 – 10:45 AM

Clinical Deep Dive: Unlocking the treatment potential of Rezdiffra

Supported by: Madrigal

Convention Center: Exhibit Hall DE, TLM Theater 2

Please join us for an engaging and highly anticipated educational panel presentation focusing on a treatment option for patients with MASH, including the clinical data and patient cases.

Discover a Treatment Option for Pruritus in patients with Alagille syndrome or PFIC

Supported by: Ipsen Biopharmaceuticals

Convention Center: Exhibit Hall DE, TLM Theater 1

Learn more about a treatment option for your patients with progressive familial intrahepatic cholestasis (PFIC) or Alagille syndrome (ALGS). Join us as Dr. Sheflin-Findling discusses an overview of PFIC and ALGS and a deep-dive into an approved treatment option for your pediatric, adolescent, and adult patients.

11 AM – 12:30 PM

Acute Liver Failure: From Mechanistic Insights to Emerging Liver Support Strategies

Convention Center: Room 146B, Level 1

This session will explore the rapidly evolving landscape of acute liver failure (ALF), addressing both the underlying pathophysiological mechanisms and cutting-edge approaches to liver support. Participants will gain insights into the immunological and metabolic contributors to ALF, including novel findings in pyroptosis and immune cell activation, as well as comorbid factors in drug-induced liver injury. The session will also highlight therapeutic innovations, including bioartificial liver systems, stem cell-derived hepatocyte technologies, and therapeutic plasma exchange. Through clinical trials and translational research, this session aims to bridge the gap between bench and bedside in the management of ALF.

MONDAY, NOVEMBER 10

11 AM – 12:30 PM

Application of Precision Immunophenotyping and Consortia Analytics in Pediatric Hepatology

Convention Center: Room 146C, Level 1

Cutting-edge clinical studies on Transplant and discoveries from consortia and registries.

Evolving Strategies in Hepatitis C: Cure, Prevention, and Beyond

Convention Center: Ballroom B, Level 3

This session highlights cutting-edge research in Hepatitis C treatment, including next-generation antivirals, optimized therapy durations, and strategies for long-term patient outcomes post-cure. Presenters will share findings from clinical trials, modeling studies, and translational research aimed at advancing the future of HCV care.

MASH Diagnostics: Advances, Limitations, and the Path Ahead, Session 2

Convention Center: Ballroom A, Level 3

'Omics' in Chronic Liver Disease

Convention Center: Room 146A, Level 1

The 'omics' revolution offers a gateway to a new level of precision medicine in chronic liver disease. In this session, we highlight six outstanding examples of genomic and metabolic explorations into pathogenesis and diagnosis of HCC on the one hand, and MASLD on the other.

Therapy for Hepatobiliary Cancers

Convention Center: Ballroom C, Level 3

Description: The therapeutic options for patients or hepatobiliary cancers are expanding, which at the same time, the impact of co-morbidity on outcome has become clearer. Participants will learn about the influence of MASLD, tumor burden and liver health on treatment success; the potential of immunotherapy in HCC and consider surgical treatment options in hepatobiliary cancers.

Global Consensus Primary Biliary Cholangitis (PBC) Endpoints – EASL/ AASLD Joint Program

Convention Center: Room 145, Level 1

The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) have jointly led a multi-stakeholder Consensus Process focused on the use of surrogate endpoints and real-world evidence in the design of clinical trials for Primary Biliary Cholangitis (PBC). This collaborative initiative culminated in a Consensus Conference held during the 2025 EASL Congress in Amsterdam, bringing together global experts, regulatory authorities, patient representatives, and industry stakeholders. This session will feature presentations of the final recommendations from this consensus process.

Next Gen Hepatology: Shaping the Future of Smarter Care with Artificial Intelligence, Telehealth, Clinical Decision Support, and Wearable Tech

Convention Center: Room 202, Level 2

Modern hepatology regularly uses diagnostic and prognostic tools in clinical practice. Artificial intelligence (AI), telehealth, clinical decision support (CDS), and remote monitoring using wearable technology are growing fields of research that can be leveraged to advance patient care and allow care teams to work more efficiently with better, more nuanced data. This session provides an overview of recent and upcoming technological innovations in the management of patients with chronic liver disease. Targeting both clinicians and researchers, this session focuses on 4 primary topics: AI-powered electronic health records, CDS tools, telehealth, and wearable technology/remote monitoring. Presentations touch on: current shortcomings in patient care and how technological applications may improve it; ongoing research; resources currently available to clinicians; future technology; and barriers to use in clinical practice. Where applicable, presenters include an overview of the US Food and Drug Administration approval process (e.g., for wearables/remote monitoring tools) and privacy concerns (e.g., for AI applications). This session aims to interweave the incredible promise of the future of health care with the difficulties of the present.

Success in Hepatology Research: From Mentorship to Academic Achievement

Convention Center: Room 207, Level 2

This focused session brings together experienced hepatology researchers to share insights on the critical elements of building a successful research career, whether pursuing a clinician-investigator or academic researcher path. Through 3 comprehensive lectures and an interactive panel discussion, participants learn essential strategies for establishing mentorship relationships, conducting impactful clinical research, and navigating the academic timeline. For clinicians maintaining busy practices, speakers address practical approaches to integrating research activities within clinical responsibilities, including strategies for protected research time and efficient study execution. For those pursuing dedicated academic research careers, the session covers establishing independent research programs, securing sustained funding, and building research teams. The session features leading experts who share their personal experiences and practical advice from both career paths, followed by an open forum where attendees can engage directly with speakers to address specific questions about research career development in hepatology.

11 – 11:30 AM

Hans Popper State of the Art: Hacking the Hepatic Lipid Code – Mechanisms and Therapeutic Opportunities in Steatotic Liver Disease

Convention Center: Hall A, General Session, Concourse Level

This presentation delves into the molecular intricacies of hepatic lipid metabolism and lipotoxicity in metabolic dysfunction associated steatotic liver disease and alcohol associated hepatitis. We will review the critical mechanistic role lipids play in liver injury and inflammation in the development of steatotic liver disease. By decoding the hepatic lipid code, the presentation aims to unveil potential therapeutic strategies. Attendees will gain insights into cutting-edge mechanisms and approaches to address liver steatosis effectively.



MONDAY, NOVEMBER 10

11:30 AM – 12:30 PM

Basic Plenary

Convention Center: Hall A, General Session, Concourse Level

12:30 – 1 PM

Biliary Atresia: How Do We Better Understand Pathways and Disease Progression?

Supported by: Ipsen Biopharmaceuticals

Convention Center: Exhibit Hall DE, TLM Theater 1

The Ipsen-sponsored TLM Theatre will explore current approaches to the management of Biliary Atresia, highlighting opportunities for further optimization of care and patient outcomes. Prognostic biomarkers and the underlying pathophysiology driving disease progression in Biliary Atresia will also be addressed.

12:30 – 2 PM

Beyond the Status Quo: Exploring the Future Impact of HBV Innovations

Supported by: Aligos Therapeutics

Organized by: Clinical Care Options, LLC

Convention Center: Room 152, Level 1

This engaging symposium will provide insights into recent innovations in the management of chronic hepatitis B. Expert faculty will discuss emerging biomarkers, investigational therapies aimed at chronic viral suppression and functional cure, and how these advances may help address existing gaps in care and improve long-term patient outcomes.

Getting to Grip with Non-Invasive Tests to Assess Liver Fibrosis & Patient Eligibility for Novel MASH Therapies

Supported by: Siemens Healthineers

Organized by: Medscape Education

Convention Center: Room 150, Level 1

Join us for a symposium on liver fibrosis designed to encourage the exchange of ideas between leaders in the field and attendees.



Women's Networking Luncheon

Sponsored by: Gilead Sciences and Madrigal Pharmaceuticals

Convention Center: Room 206, Level 2

Join us for an inspiring and empowering luncheon dedicated to celebrating women in hepatology. Connect with other female hepatologists by engaging in meaningful conversations about career growth and challenges, and be part of a vibrant community driving change in the field.

12:45 – 1:15 PM

HCC Immunotherapy as a Bridge to LT

Convention Center: Science in the Park, Site B, Level 3

Come discuss the pros, cons, knowns, and unknowns of HCC immunotherapy in liver transplantation.

Abstract Highlights Station: Liver Fibrosis SIG

Convention Center: Science in the Park, Site A, Level 3

The SIG Abstract Highlights Station gives each of AASLD's 16 Special Interest Groups (SIG) the opportunity to deliver a 30-minute, in-person presentation spotlighting their top three abstracts.

12:45 – 1:30 PM



MTE #36 Special Considerations in the Management of Cystic Fibrosis Liver Disease

Convention Center: Room 140A, Level 1

Cystic fibrosis hepatobiliary involvement (CFHBI) occurs in up to 90% of people with cystic fibrosis. Advanced cystic fibrosis liver disease is present in approximately 10% of people with cystic fibrosis. CFHBI is the third leading cause of morbidity and mortality in people with cystic fibrosis; early diagnosis and surveillance for disease progression are essential to optimize patient outcomes. Experts conducting this session review the current guidelines for monitoring CFHBI; the algorithm of care related to cystic fibrosis transmembrane conductance regulator protein modulator therapy hepatotoxicity; and the diagnostic and therapeutic options for managing advanced cystic fibrosis liver disease.



MTE #37 Pushing Boundaries: Oncology and Liver Transplantation – Opportunities and Challenges

Convention Center: Room 140B, Level 1

Liver transplantation for malignancies – including metastatic colorectal cancer neuroendocrine tumors – is an emerging area of interest in oncology and transplant medicine. Speakers delve into the latest advancements, clinical outcomes, and patient selection criteria for this innovative approach. Experts share insights into the current evidence, ongoing clinical trials, and the multidisciplinary strategies needed to optimize patient outcomes. The session also includes an in-depth discussion on the feasibility, ethical considerations, and future directions of transplant oncology.



MTE #38 Cell Senescence in Liver Disease

Convention Center: Room 144C, Level 1

Cell stress can lead to proliferative arrest (senescence), which can accelerate disease progression through a variety of mechanisms. Subject matter experts explore triggers and pathways that convert cells to a senescent, secretory phenotype. Session topics include characteristics of cell senescence; the role of cellular senescence in the progression of chronic liver injury; types of cell populations affected (hepatocytes, cholangiocytes, hepatic stellate cells, and others); beneficial and harmful effects of cell senescence; molecular mechanisms; and potential therapeutic strategies.



MTE #39: Fontan-Associated Liver Disease: When to Consider Combined Heart and Liver Transplant

Convention Center: Room 149, Level 1

Experts review the pathophysiology of Fontan-associated liver disease and the associated risk of developing hepatocellular carcinoma. Presenters also discuss the management of Fontan-associated liver disease, indications for combined heart and liver transplantation, and posttransplant outcomes.

MONDAY, NOVEMBER 10

12:45 – 1:30 PM

MTE #40 Metabolic Dysfunction-Associated Steatohepatitis Therapeutic Agents: What Is Available and What Is Next in Line?

Convention Center: Room 154, Level 1

This session focuses on the nuances of selection of therapies for MASH and metabolic complications. Topics include the experience garnered following the US Food and Drug Administration approval of resmetirom and new therapeutic agents currently in phase 3 clinical trials.

MTE #41 What's New in Pediatric Liver Transplant Guidelines

Convention Center: Room 158, Level 1

Experts and attendees discuss key updates included in the 2025 AASLD guidelines for pediatric liver transplant including evaluation of pediatric patients for liver transplantation and long-term management of pediatric liver transplant recipients.

1 – 2 PM

Monday Poster Presenter Presentation Hour

Convention Center: Hall DE (Posters & Exhibits), Level 2

The following poster categories will be in the Poster Hall:

- o Acute Liver Failure and Artificial Liver Support
- o Acute on Chronic Liver Failure
- o Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis
- o Cell and Molecular Biology
- o Genomics and Precision Medicine
- o Gut Liver Axis and Microbiome
- o Hepatotoxicity
- o Human Cholestatic and Autoimmune Liver Diseases
- o Inflammation and Immunobiology
- o MASLD/MASH -Therapeutics: Approved/available agents
- o Pediatric Hepatology
- o Therapeutics: New Agents – MASLD and MASH
- o Vascular Liver Disease, Hemostasis and Thrombosis

2 – 6 PM

Point-of-Care Liver Ultrasonography Course: Advanced Skills

Marriott Marquis: Marriott Marquis Ballroom, Salons 1-5

This workshop provides advanced training for use of liver point-of-care ultrasonography (POCUS) and is intended for professionals who have previously completed the basic skills liver POCUS courses at The Liver Meeting or Digestive Disease Week. The workshop includes a theoretical portion focusing on assessment of inpatient liver findings using POCUS, liver electrography, and advice on implementing liver POCUS in clinical practice. A hands-on session follows with an approach to specific liver findings instead of normal liver anatomy. The workshop concludes with a question-and-answer period.

IMPORTANT NOTE: To register for this session, participants must either be registered for the Basic Skills Liver POCUS Workshop at The Liver Meeting 2025 or have previously completed a Basic Skills Liver POCUS Workshop at The Liver Meeting 2024 or Digestive Disease Week 2025.

2 – 3:30 PM

60th Anniversary of the Discovery of the Hepatitis B Virus

Convention Center: Ballroom C, Level 3

This session will review the key events leading to the discovery of the hepatitis B virus, the global public health impact HBV has had on human health, the development of an effective vaccine to prevent transmission that has reduced incident infection in endemic regions, and the state of current elimination efforts. Faculty members will also cover the history of the development of therapy for HBV and the effectiveness of current therapy to prevent complications of chronic HBV infection. Finally, new therapies in development for a cure for chronic HBV infection will be reviewed.

Clinical Research Workshop: Advancing Research Frameworks in MetALD, Part 1 – Key Strategies for Refining Risk and Integrating Biomarkers

Convention Center: Room 207, Level 2

Join experts providing a comprehensive overview of MetALD, i.e., combined metabolic dysfunction-associated and alcohol-associated liver disease. Presenters highlight key considerations for developing robust research programs; leveraging biomarkers and omics technologies; and understanding the interplay between alcohol use, metabolic dysfunction, and liver disease progression. Speakers discuss emerging insights into risk stratification, cohort development, and the relationship between MetALD and HCC. The workshop aims to integrate translational and clinical research approaches, equipping attendees with knowledge to enhance precision medicine strategies in MetALD.



MONDAY, NOVEMBER 10

2 – 3:30 PM

High Stakes, New Strategies: Tackling Severe Alcohol-Associated Hepatitis

Convention Center: Ballroom B, Level 3

This meeting session will explore emerging research on alcohol-associated liver disease (ALD), with a focus on severe alcohol-associated hepatitis (SAH). The session will highlight long-term outcomes following hospitalization and early liver transplantation for SAH, as well as introduce a novel therapeutic approach to its treatment. Additionally, it will examine a newly identified genetic risk modifier for ALD and investigate the potential influence of cannabis use on disease risk. Together, these abstracts aim to deepen understanding of disease mechanisms, treatment strategies, and risk factors in ALD.

Improving Liver Disease Care: Mental Health, Education, and Value-Based Models

Convention Center: Room 146B, Level 1

This session explores the intersection of mental health, stigma, and innovative care models in chronic liver disease. Presenters will share research and strategies aimed at improving quality of life and clinical outcomes through patient education, timely interventions, and integrated, value-based care.

Integrated Perspectives on Vascular Liver Disorders

Convention Center: Room 146A, Level 1

This session encompasses basic, translational, and clinical studies in vascular liver disease and portal hypertension. Ranging from congestive hepatopathy and cirrhosis in fontan-associated liver disease to intrahepatic molecular pathways of fibrosis in chronic liver disease. Key areas also include examination of porto-sinusoidal vascular liver disease and TIPS for acute and chronic portal vein thrombosis.

Lessons Learned from Large International Registries of Pediatric Liver Diseases

Convention Center: Room 146C, Level 1

Speakers present diverse registry-based studies in liver disease with the objectives to disseminate evidence-based practice knowledge and enhance collaboration. Study data from the Global Alagille Alliance (GALA) study, the International Registry of Congenital Porto-Systemic Shunts (IRCPSS), and the International Multicenter Pediatric Portal Hypertension Registry (IMPPHR) are reviewed.

Late Breaking Oral Abstract Session #1

Convention Center: Hall A, General Session, Concourse Level

Management of Portal Hypertension: From Considerations in MASLD and the Assessment of Frailty

Convention Center: Room 202, Level 2

MASH: Natural History, Life Style and Large Real World Data (1)

Convention Center: Ballroom A, Level 3

Novel Therapies and Monitoring in Cholestatic Disease

Convention Center: Room 145, Level 1

A series of reports on the exploration of new agents in AIH and PBC, along with intriguing data on enhanced monitoring in cholestatic disorders.

3:30 – 4:15 PM

Advancing Treatment in Primary Biliary Cholangitis (PBC): Insights into a Selective PPAR δ Agonist

Supported by: Gilead Sciences

Convention Center: Exhibit Hall DE, TLM Theater 1

Join us for a product theater on an FDA-approved treatment option for primary biliary cholangitis (PBC). Gain insights into how this therapy may support improved PBC outcomes for the appropriate patients affected by this chronic liver disease.

More Than Fat in the Liver: The Metabolic Burden of Excess Adiposity Industry

Supported by: Boehringer Ingelheim Pharmaceuticals, Inc.

Convention Center: Exhibit Hall DE, TLM Theater 2

Explore the metabolic connections between obesity, MASLD/MASH, and cardiometabolic diseases, and how incorporating obesity care in hepatology practice can improve multiple health outcomes. Join expert clinicians for an in-depth discussion on the vital role of hepatology in obesity care and the importance of collaborative care.

3:45 – 4:15 PM

AASLD Practice Guideline on Treatment of Chronic Hepatitis B

Convention Center: Science in the Park, Site B, Level 3

Come discuss the upcoming AASLD guideline on treatment of chronic hepatitis B with the co-chairs of the guideline. What has changed?

MONDAY, NOVEMBER 10

3:45 – 4:45 PM

Clinical Research Workshop: Advancing Research Frameworks in MetALD Breakout Session, Part 2A – Designing Cohort Studies in MetALD

Convention Center: Room 207, Level 2

Experts provide an overview of the latest innovations in study design in MetALD-induced liver disease, including study endpoints. Presenters explore how to design and conduct effective cohort studies, large database studies, and clinical trials. Topics include the role of investigator-initiated cohort studies, large national database studies, and clinical trials in MetALD with discussion of funding opportunities, monitoring, and conducting these studies with a focus on early-stage investigators. This interactive session provides an opportunity to discuss study methodologies, existing studies, and protocols with the moderators.

Clinical Research Workshop: Advancing Research Frameworks in MetALD Breakout Session, Part 2B – Large Database Studies in MetALD

Convention Center: Room 202, Level 2

Experts provide an overview of the latest innovations in study design in MetALD-induced liver disease, including study endpoints. Presenters explore how to design and conduct effective cohort studies, large database studies, and clinical trials. Topics include the role of investigator-initiated cohort studies, large national database studies, and clinical trials in MetALD with discussion of funding opportunities, monitoring, and conducting these studies with a focus on early-stage investigators. This interactive session provides an opportunity to discuss study methodologies, existing studies, and protocols with the moderators.

Clinical Research Workshop: Advancing Research Frameworks in MetALD Breakout Session, Part 2C – Designing Clinical Trials in MetALD

Convention Center: Room 145, Level 2

Experts provide an overview of the latest innovations in study design in MetALD-induced liver disease, including study endpoints. Presenters explore how to design and conduct effective cohort studies, large database studies, and clinical trials. Topics include the role of investigator-initiated cohort studies, large national database studies, and clinical trials in MetALD with discussion of funding opportunities, monitoring, and conducting these studies with a focus on early-stage investigators. This interactive session provides an opportunity to discuss study methodologies, existing studies, and protocols with the moderators.

Early Career Investigator Essentials: Adapting and Excelling in Challenging Times

Convention Center: Room 146C, Level 1

In an era of rapid change and uncertainty, the ability to adapt and excel is crucial for early career investigators seeking sustained success. This community conversation focuses on strategies for maintaining productivity, resilience, and innovation amid evolving professional and personal landscapes. Panelists provide actionable insights to help attendees navigate uncertainty, embrace change, manage stress and burnout, and drive meaningful progress in their work when faced with setbacks or barriers.

Hepatology Associates Meet-Up

TLM at the Park, Meet-Up #6

Connect. Collaborate. Engage. Join fellow hepatology associates for an informal and energizing Meet-Up at The Liver Meeting. Whether you're focused on research, clinical care, or both, this is your chance to network with peers, spark new ideas, and explore collaborative opportunities in a relaxed setting. Don't miss it!

Recruiting and Retaining Women in Hepatology: Essential Strategies for Division Chiefs and Academic Leaders

Convention Center: Room 201, Level 2

As the majority of transplant hepatology trainees are women, it is essential to focus on recruiting and retaining this talented group to ensure a thriving hepatology division. Evidence highlights that workplace bias, family-unfriendly work environments, and gender pay inequities are significant challenges that need to be addressed. This community conversation begins with a brief expert review of the evidence behind workplace gender inequities and exploration of successful structural solutions. A diverse panel – including division chiefs with successful recruitment records, a female fellow trainee, an early-career female physician, and a mid-career female physician – then share their experiences with fellowship applications and job searches.

Risk Stratification in Metabolic Dysfunction-Associated Steatohepatitis: Early Versus Late Fibrosis

Convention Center: Room 146B, Level 1

Experts examine the importance of fibrosis staging in the risk assessment and management of metabolic-associated steatohepatitis (MASH). The session explores the clinical implications of focusing on early-stage versus late-stage fibrosis; evaluates the role of advanced diagnostic tools in stratifying risk; and reviews how targeted approaches can improve patient outcomes. This community conversation aims to impart a deeper understanding of how to prioritize interventions based on fibrosis severity and emerging evidence.

Special Interest Group (SIG) Meet-Up #3

Convention Center: The Park @ TLM, Meet-Up #1-6, Level 2

Join your SIG Meet-Up, where you can connect with professionals who share your research and clinical interests! Enjoy light snacks, fun games, and great conversations in a relaxed, informal setting – perfect for networking and building new connections.

- o Meet-Up 1: Hepatotoxicity
- o Meet-Up 2: HBV
- o Meet-Up 3: PLD
- o Meet-Up 4: ACLF
- o Meet-Up 5: Liver Cancer
- o Meet-Up 6: Hepatology Associates



MONDAY, NOVEMBER 10

3:45 – 4:45 PM

Simplifying Hepatitis C Care in 2025

Convention Center: Room 206, Level 2

Presenters highlight key updates contributing to the simplification of hepatitis C treatment in 2025, including: (1) diagnostic approaches across episodic and long-term health care settings; (2) workup and treatment; and (3) integrated opioid use disorder care and hepatitis C treatment to achieve hepatitis C elimination.

Tech and Tweets: Navigating the Future of Hepatology in a Digital World

Convention Center: Salon GH, Level 1

In an ever-evolving digital landscape, staying connected and innovative is essential for advancing hepatology. This interactive session explores how social media and emerging technologies can shape the field, enhance professional collaboration, and improve patient care. The session begins with an overview of AASLD's current digital initiatives including highlights of the Tech and Communication Committees and the emerging Informatics Interest Group. Presenters then take a deep dive into the shifting social media landscape in hepatology, including the migration from Twitter (X) to newer platforms like Bluesky and the growing impact of short video platforms. Discover strategies to maintain a vibrant social media community in hepatology while effectively using these new tools for networking, advocacy, and patient education. Speakers also explore cutting-edge technologies revolutionizing hepatology. From artificial intelligence (AI)-driven diagnostics to smartphone apps and advanced electronic health records (EHR) applications, this presentation highlights the transformative potential of tech innovations in daily clinical practice. The session concludes with an open floor discussion, inviting attendees to share their insights, challenges, and ideas on leveraging digital tools like social media, AI, and other technology applications to better serve AASLD members and communities.

5 – 6:30 PM

Acute on Chronic Liver Failure

Convention Center: Room 146B, Level 1

Beyond Viral Suppression: Predictors of HBV Outcomes, Cure Potential, and HCC Risk

Convention Center: Room 207, Level 2

This session will explore how clinical and molecular markers can inform prognosis and therapeutic strategy in chronic hepatitis B. Presentations will compare the impact of current antiviral therapies on hepatocellular carcinoma (HCC) risk and examine how partial virologic responses and HBsAg decline correlate with long-term outcomes. The session will also address the evolving role of therapy discontinuation in HBeAg-negative patients, the utility of quantitative HBsAg and HBV RNA in distinguishing inactive carriers from those with partial cure, and the predictive value of biomarkers in selecting candidates for functional cure.

Liver Transplant and Chronic Liver Disease Disparities

Convention Center: Room 146A, Level 1

This session explores national and local drivers of disparities in access to liver transplant and chronic liver disease care, as well as potential solutions.

MASH: Natural History , Life Style and Large Real World Data (2)

Convention Center: Ballroom B, Level 3

Novel Approaches and Discoveries in Pediatric Hepatology

Convention Center: Room 146C, Level 1

Basic and translational pediatric hepatology.

Portal Hypertension and Other Complications of Cirrhosis: Experimental and Translational

Convention Center: Room 202, Level 2

Toward 2030: Collaborative Solutions for Hepatitis C Diagnosis, Care, and Elimination

Convention Center: Ballroom C, Level 3

This session presents innovative and collaborative approaches to achieving global Hepatitis C elimination for adults and children. Presenters will share insights on diagnostic strategies, care linkage, and progress toward the WHO 2030 targets, highlighting efforts across clinical, public health, and global contexts.

Pediatric Liver Disease Debrief

Convention Center: Room 146C, Level 1

Late Breaking Oral Abstract Session #2

Convention Center: Hall A, General Session, Concourse Level

5 – 6 PM

TLM Debrief 1: Liver Transplantation and Portal Hypertension

Convention Center: Ballroom A, Level 3

The debrief sessions summarize the highest impact papers addressing key topics across the field of hepatology presented during The Liver Meeting. A group of original research reports reflecting major advances in hepatology are succinctly reviewed. Debrief 1 will cover pediatric liver disease, liver transplantation, and portal hypertension.

MONDAY, NOVEMBER 10

6:30 – 7:30 PM

Diversity Reception

Marriott Marquis: University of DC and Catholic University

Join us at this reception hosted by AASLD's Inclusion and Diversity Committee to celebrate the rich experiences and perspectives within the hepatology community. Connect with colleagues, share your journey, and engage in thoughtful conversation in a space that values connection, respect, and belonging.

TUESDAY, NOVEMBER 11

8 – 11 AM

TLM Debrief 2: Basic Science, Hepatitis, HCC, Cholestatic, MASLD, Alcohol-Associated Liver Disease and MetALD Debrief

Convention Center: Hall A, General Session, Concourse Level

The debrief sessions summarize the highest impact papers addressing key topics across the field of hepatology presented during The Liver Meeting. A group of original research reports reflecting major advances in hepatology are succinctly reviewed. Debrief 2 will address basic science research, hepatitis, hepatocellular carcinoma, cholestatic liver disease, alcohol-associated liver disease and MetALD, and metabolic dysfunction-associated liver disease.

11 AM – Noon

Late Breaking Oral Abstract Session #3

Convention Center: Hall A, General Session, Concourse Level



EXHIBIT HALL: INNOVATION IN ACTION

Connect with leading liver health exhibitors and discover solutions driving real impact.

COMPANY NAME	BOOTH NUMBER
89bio	851, MR20
AASLD Hub	916
AbbVie	520
AcariaHealth Specialty Pharmacy	626
Akero Therapeutics	1036
ALEH	1148
Alexion, AstraZeneca Rare Disease	649
Aligos Therapeutics	754
Almac Group	439
Alpha-1 Foundation	1159
Altimune	948
American Liver Foundation	1452
American Porphyria Foundation	1151
Amgen	445
Amsety LLC	959
Asian Pacific Association for the Study of the Liver (APASL)	1149
AstraZeneca	532, MR2, MR31, MR32
Atea Pharmaceuticals	839, MR1
Autoimmune Hepatitis Association	1248
Avant Santé	961

COMPANY NAME	BOOTH NUMBER
Bausch Health – Salix Medical Affairs	622
BD	536
Beijing Vitalstar Biotechnology Co.,Ltd.	1550
Bionews – Liver Disease News	1350
BioPorto Diagnostics	751
BioPredictive	429
Blue Faery	1252
Boehringer Ingelheim International GmbH	MR43
Boehringer Ingelheim Pharmaceuticals Inc.	757, MR28, MR44
Bristol Myers Squibb	1027, MR40
Cepheid	630
Cholangiocarcinoma Foundation	1352
Chronic Liver Disease Foundation	1446
Cima Sciences	761
Coalition For Global Hepatitis Elimination, Task Force For Global Health	1347
Community Liver Alliance	1249
Cook Medical	741
Cour Pharmaceuticals	548
Cytotheryx, Inc.	627
Diasorin	941
Dose	1159
DTR Labs	942
Dynavax Technologies	752

COMPANY NAME	BOOTH NUMBER
EarlyDx	1154
Echosens	525
Eieling Technology Limited	843
Eisai Inc.	606
Eli Lilly and Company	542, MR9
E-Scopics	436
Eton Pharmaceuticals	952
European Association for the Study of the Liver (EASL)	1146
Exact Sciences	1026
Exelixis	739
Federation of American Societies for Experimental Biology (FASEB)	1046
Fibronostics- LiverFAST	549
Forum for Collaborative Research	1247, 1348
FUJIFILM Healthcare Americas Corporation	522
Fujifilm VisualSonics Inc	854
GALAXY ZERO	537
Gastroenterology & Endoscopy	637
Gastro-Hep Communications Inc	928
GE HealthCare	545
Genentech	736
Gilead Sciences, Inc.	700, MR21, MR29, MR36, MR38, MR39, MR42
Global Liver Institute	1250
Gore & Associates / WL Gore	625

COMPANY NAME	BOOTH NUMBER
GSK	509, MR5, MR6
HealthWell Foundation	1346
Helio Genomics	1042
Hepatiq Inc.	412
HepQuant	1039
HISKY Medical	409
HistoIndex	645
HistoSonics Inc	1257
ICON	1041
IIAM	1051
ImCare Biotech	1045
InBody BWA, Inc	414
Intercept Medical Affairs	506, MR35
Intercept Pharmaceuticals, Inc.	400, MR34
International Liver Transplantation Society	1448
Inventiva	745, MR4
Ipsen Biopharmaceuticals Inc.	709, MR11, MR12, MR13, MR7, MR8
IV Solutions RX	413
KBI	1158
Kezar Life Sciences	951
KlinEra	1546
Kunming Biomed International	1058
Labcorp	648

COMPANY NAME	BOOTH NUMBER
Liver Action Network – GLI	1251
Liver Education Advocates	1351
Liverpool Drug Interactions	1049
Livivos Inc	748
Luminos Pro	427
Madrigal Pharmaceuticals	720, MR17, MR18, MR19, MR27
Mallinckrodt Pharmaceuticals	539
Metabolic Solutions	947
Methodist Hospital Specialty Transplant	1157
Metware Biotechnology Inc	1043
Miltenyi Biotec	629
Mindray	430
Mirum Pharmaceuticals	500, MR26, MR33
MNK Medical Affairs	842
Nordic Bioscience	945
Northwell Health	426
Northwestern Medicine	743
Novo Nordisk Medical Affairs	957
Novo Nordisk, Inc	730, MR14, MR22, MR23, MR30
Organ Recovery Systems	1354
Orphalan US	936, MR24
Owlstone Medical	940
PathAI	926

COMPANY NAME	BOOTH NUMBER
Patient Access Network Foundation	1451
PBC Foundation	1447
PBCers Organization	1052
Perspectum	726
PhoenixBio	422
Precisionary Instruments LLC	1255
Prometheus Laboratories	763
PSC Partners Seeking a Cure	1152
Purity Coffee	749
Recordati Rare Diseases	636
REGENERON	943, MR3
Research Diets Inc.	640
Resoundant Inc.	421
Revvity	540
Rocky Mountain Poison and Drug Safety	1048
RWJBH	1549
Salix Pharmaceuticals	716
Sequana Medical US Inc	848
Siemens Healthineers	529, MR37
Sonic Incytes	826
Summit Clinical Research	1155
Takeda	404, MR10
Takeda Transplant	954

COMPANY NAME

BOOTH NUMBER

Target RWE	742
TGH Transplant Institute	1454
TransCure bioServices	841
Ultragenyx	1054
United Porphyrias Association	1047
University of Miami Health System	1161
UPMC Presbyterian	1028
Vir Biotechnology, Inc.	1254, MR16, MR25
Wave Life Sciences	762
World Gastroenterology Organisation	1246
WuXi AppTec	939
Yecuris	740
Zenas Bio	1547
Zydus Therapeutics Inc	651

**VIEW THE EXHIBIT HALL
MAP ONLINE, SCAN NOW**



BIG IMPACT, SUPPORTED BY SPONSORS

GOLD SPONSORS



Boehringer
Ingelheim



GILEAD

GSK



IPSEN



Madrigal



SPONSORS

89bio

abbvie

akero



Catalyst
MEDICAL EDUCATION



BD



powered by CEA



HEPATIQ®
The Ultimate Liver Test™



HealthProMatch

Intercept
ALFASIGMAGROUP


KEZAR
LIFE SCIENCES



VCU

Medscape
EDUCATION

SIEMENS
Healthineers



zydus
Therapeutics

#TLM25 sponsors as of October 10, 2025.

YOUR GUIDE TO #TLM25

Essential event services to keep you connected, prepared, and on track.

BEACON TECHNOLOGY

AASLD is using event badge beacons to replace badge scanning. AASLD will match the beacon with your attendee ID to track sessions you attend, which will aggregate beacon data to gauge overall interest in content. Data captured will be used to determine traffic patterns, room capacities, and inform future event programming of The Liver Meeting®. All attendee data is confidential. No data or information will be distributed or shared externally by AASLD or the vendor (TurnoutNow). The data will be deleted 30 days after The Liver Meeting®, and no other third parties will have access to it. Attendees may request a badge without beacon technology. Visit the registration desk for assistance.

For more information on beacon technology, including how AASLD will utilize the data in real-time and in the future, visit The Liver Meeting website or registration desk onsite.

WI-FI

NETWORK: AASLD

PASSWORD: MASH2025

Sponsored by



Madrigal

FIRST AID

First Aid is available throughout the Convention Center during The Liver Meeting, with the main office located in Hall D.

LOST & FOUND

Lost and left-behind items may be found at Registration, located in the Grand Lobby near Salon ABC Pre-Function. At the end of the meeting, all items will be turned over to Walter E. Washington Convention Center security.

IN CASE OF EMERGENCY

Dial 3333 from any house phone inside the convention center or **call 202-249-3333** from your cell phone.

Do not call 9-1-1 directly; inform Convention Center/ Guest Services of the nature and location of the emergency.

BAG & COAT CHECK

Bag & Coat Check, located by Registration in Salon GHI Pre-Function, is available Friday from 6:30 AM to 6:30 PM, Saturday from 6:30 AM to 8:30 PM, Sunday and Monday from 6:30 AM to 7:30 PM, and Tuesday from 7 AM to 12:30 PM. Please note, electronics are not permitted.

EXCLUSIVE MEMBER BENEFITS AT #TLM25

AASLD MEMBER LOUNGE

Enjoy a quiet space to network, work, or unwind between sessions at the Member Lounge located in Salon B on the street level, open Friday through Monday from 7 AM to 6 PM.

SIG BUSINESS MEETINGS

Are you a SIG member? Be sure to join us at your respective SIG business meeting(s) during TLM! These meetings are a great opportunity to connect with SIG leaders and fellow members, discuss specialty-specific topics, and contribute to planning next year's sessions.

SHARE YOUR EXCITEMENT ON SOCIAL

Stay ahead in liver health and connect with colleagues online — tag AASLD and use #TLM25 in your posts to double the IMPACT.



@AASLDNews.Bsky.Social



@AASLDNews



@AASLD



@AASLD

MEMBERS' RECEPTION

Sunday, Nov. 9, beginning at 7:30 PM at The National Building Museum. Share ideas, expand your network and dress for IMPACT by wearing black, white, or gold.

WHAT DOES TLM MEAN TO YOU?

Members like you are the heart and the voice of TLM — and we want to hear from you! Share what you love most about this critical gathering, then stop by the AASLD Booth #916 in Exhibit Hall D to collect a small token of our appreciation. It only takes a minute with the short form below.



**SHARE
YOUR
STORY**



**BECOME A
MEMBER TODAY!**



HONORING HISTORY. DRIVING IMPACT.

**YOU'RE INVITED TO ATTEND THE
AASLD MEMBERS' RECEPTION!**

Sunday, November 9 | 7:30-11:30 PM
The National Building Museum

**DRESS FOR IMPACT:
WEAR BLACK, WHITE, OR GOLD**

Supported in part by





Denver, CO

PLAN AHEAD – NEW DATES FOR #TLM26

THURSDAY, NOV. 5-MONDAY, NOV. 9, 2026

SIGN-UP NOW TO RECEIVE
TLM UPDATES DIRECTLY
TO YOUR INBOX.

